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Tau is an intrinsically disordered protein found mainly in neurons, composed of four main domains, the Nterminal domain, the proline rich region, the microtubule binding region, and the C-terminal domain. Tau
regulates the dynamic instability of microtubules by facilitating the polymerization of tubulin. Tau is also a
key component of the aggregates found in several neurodegenerative diseases collectively known as
tauopathies, the most prevalent of which is Alzheimer’s disease. In this disease pathology, normally
soluble tau aggregates to form insoluble neurofibrillary tangles. The presence of aggregated tau spreads
from one region of the brain to another suggesting that tau propagates from cell to cell. Understanding
the mechanisms by which tau interacts with microtubules and the aggregation pathway leading to the
spread of disease pathology is vital for diagnosis and treatment of tauopathies. In this work, we primarily
use single molecule fluorescence techniques to study three mechanisms of tau. We studied the initiation
of aggregation of tau in the presence of polyphosphates, a biologically relevant polyanionic molecule. We
find that the proline rich region contains multiple binding sites and contributes to the three mechanisms
by which polyphosphates can initiation aggregation; a change in conformation towards a more
aggregation-prone conformation, charge-screening to increase local concentrations of tau, and
intermolecular crosslinking. We also studied the propagation of monomer tau between neuronal cells. We
find that the proline rich region of tau has a unique ability to diffuse passively through a lipid membrane,
and that tau has higher affinity to lipid membranes with more ordered structure, higher cholesterol
content mimicking lipid rafts. Lastly, we investigated the effects of the R5L mutation on tau’s binding to
tubulin. We find that the mutation found on the N-terminal domain of the protein doesn’t affect binding
affinity to microtubules or tubulin in high molarity buffers but has a higher affinity for tau in the 3R isoform
of tau in a low salt buffer. Together, this provides us with an insight into the importance of the domain
dependence of tau in its functions and dysfunctions, as well as an insight into tau’s preference for binding
partners.
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ABSTRACT
SINGLE MOLECULE APPRAOCHES TO STUDYING TAU FUNCTION AND
DYSFUNCTION
Sanjula Wickramasinghe
Dr. Elizabeth Rhoades

Tau is an intrinsically disordered protein found mainly in neurons, composed of
four main domains, the N-terminal domain, the proline rich region, the microtubule
binding region, and the C-terminal domain. Tau regulates the dynamic instability of
microtubules by facilitating the polymerization of tubulin. Tau is also a key component of
the aggregates found in several neurodegenerative diseases collectively known as
tauopathies, the most prevalent of which is Alzheimer’s disease. In this disease
pathology, normally soluble tau aggregates to form insoluble neurofibrillary tangles. The
presence of aggregated tau spreads from one region of the brain to another suggesting
that tau propagates from cell to cell. Understanding the mechanisms by which tau
interacts with microtubules and the aggregation pathway leading to the spread of disease
pathology is vital for diagnosis and treatment of tauopathies. In this work, we primarily
use single molecule fluorescence techniques to study three mechanisms of tau. We
studied the initiation of aggregation of tau in the presence of polyphosphates, a
biologically relevant polyanionic molecule. We find that the proline rich region contains
multiple binding sites and contributes to the three mechanisms by which polyphosphates
can initiation aggregation; a change in conformation towards a more aggregation-prone
iii

conformation, charge-screening to increase local concentrations of tau, and
intermolecular crosslinking. We also studied the propagation of monomer tau between
neuronal cells. We find that the proline rich region of tau has a unique ability to diffuse
passively through a lipid membrane, and that tau has higher affinity to lipid membranes
with more ordered structure, higher cholesterol content mimicking lipid rafts. Lastly, we
investigated the effects of the R5L mutation on tau’s binding to tubulin. We find that the
mutation found on the N-terminal domain of the protein doesn’t affect binding affinity to
microtubules or tubulin in high molarity buffers but has a higher affinity for tau in the 3R
isoform of tau in a low salt buffer. Together, this provides us with an insight into the
importance of the domain dependence of tau in its functions and dysfunctions, as well as
an insight into tau’s preference for binding partners.
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1 Chapter 1: Introduction
2.1 Intrinsically disordered proteins
Intrinsically disordered proteins (IDPs) are a subgroup of proteins, first
discovered in the 1950s but not studied extensively until about 20 years ago (1-3). IDPs
are proteins characterized by the lack of stable secondary or tertiary interactions and are
better described as pliable proteins with the ability to adopt transient conformations under
different environmental and binding conditions. As the study of proteins was often driven
by relating function to the characterization of the secondary structure with the
development of X-ray crystallography and NMR, many proteins and their novel functions
were left unstudied for decades. However, as the interest in IDPs grew, the importance of
IDPs and intrinsically disordered regions within structured protein came into prominence
(1). This challenged the belief that proteins have and need a rigid structure to allow it to
carry out its native function. We now know that >40% of the mammalian proteome can
be classified as IDPs, or contain an IDR (4). In fact, IDPs are now implicated in a wide
variety of necessary biological phenomena including but not limited to, cell signaling and
cascades (5), the dynamic assembly of membrane-less organelles (6), the regulation of
macromolecular machinery such as ribosomes (7), the organization of chromatin (8,9),
the assembly and disassembly of the cytoskeleton of microtubules and microfilaments
(10,11), and the functioning of chaperone proteins (12).
The amino acid sequences of IDPs can provide an insight into whether a protein is
likely to be natively unfolded. IDPs tend to have fewer hydrophobic amino acids, and
more polar and charged residues within their sequences compared to proteins that adopt
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globular folded structures (13). However, IDPs can adopt transient conformation, which
combined with their disordered nature has been suggested to play a vital role in their
function (14). Therefore, studying the conformational landscapes that disordered proteins
can occupy is vital to understanding how these proteins function, and in some cases, lose
their function leading to disease pathology.
However, since IDPs occupy transient conformations and are very susceptible to
environmental conditions, they remained difficult to study with established structural
techniques such as Xray crystallography and Nuclear Magnetic Resonance (NMR). The
dynamic nature of IDPs and the heterogeneous mixture of conformations they occupy
make studying IDPs with X-ray crystallography not possible. While NMR has proved
useful insights into studying some IDPs (15-17), the information that can be obtained by
NMR is limited by the requisite protein concentrations and buffer conditions.
Several methods have been developed in recent years to aid in the study of IDPs.
Cryro-EM has been used to study some IDPs bound to their molecular binding partners to
provide insight into the native functions (18,19). Molecular simulations are another
useful tool to investigate molecular ensembles and disorder to order transitions of IDPs
(20,21). Single molecule fluorescence techniques have proved extremely useful as it
allows for the measurement of very low concentrations of protein, and the nature of
fluorescence allows the recording of transient conformations. One of the most useful
techniques that has been used is single molecule Förster Energy Transfer (smFRET).
SmFRET was first published in 1996 as a way to eliminate ensemble averaging of
samples by looking at the rotation and changes in distance of single pairs of fluorescent
probes at the nanometer scale (22). It has since been used to study a wide range of
2

biological phenomena including native functions involving RNA and DNA, protein
folding, function and aggregation, motor proteins, signal transduction and membrane
proteins (23-26).
In FRET measurements, non-radiative transfer of energy via a dipole-dipole
interaction from a donor fluorophore to an acceptor fluorophore. The efficiency of energy
transfer is dependent on the distance between the two fluorophores. In smFRET, this is
calculated as ETeff = (1 / (R +Ro)6)-1 where ETeff is the efficiency of energy transfer, R is
the inter-dye distance, and Ro is the Förster radius at which ETeff= 0.5 (26). An additional
advantage of smFRET is that measurements can be done at very low concentrations in
solution with freely diffusing fluorescently labeled molecules diffusing through the focal
volume of the laser or with surface stabilized molecules and the use of total internal
reflection microscopy (23).
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2.2 Tau is an Intrinsically Disordered Protein
The scope of this research focuses mainly on the intrinsically disordered protein
Tau. First identified in 1975, tau is also categorized as a microtubule associated protein
(MAP) necessary for microtubule function (27). Tau is composed of 4 distinct domains,
the negatively charged N-terminal domain, the proline rich region (PRR), the microtubule
binding domain containing 4 repeat regions (MTBR), and the C-terminal domain (Fig 11).
The human tau gene is located on chromosome 17 which gives rise to six possible
isoforms expressed in adult human brains. Alternative splicing out of exons 2 and 3
removes one or two inserts in the N-terminal domain (N1 and N2 respectively) and exon
3 is never present without exon 2, giving rise to 0N, 1N or 2N isoforms. Alternative
splicing of exon 10 results in the removal of the second repeat region within the MTBR
(R2) resulting in 3R or 4R isoforms (28). In healthy adult humans, the 3R and 4R
isoforms are found in equal ratios (29-31) and an imbalance of the ratio of 3R to 4R
isoforms has been implicated in some neurodegenerative diseases (32). Additionally, only
the shortest isoform, 0N3R, is found in fetal brains. This ratio is also unique to adult
human brains, as rodent tauopathy models only express the 3R isoforms of tau (32).
Tau is fully disordered but can adopt transient conformations in different buffer
conditions and upon binding to its binding partners (33). In solution, tau adopts an Sshaped or paperclip conformation in which the N-terminal and C-terminal domains fold
over the PRR and MTBR (33,34). Upon binding to tubulin or polyanionic molecules such
as heparin, the PRR and MTBR undergo a compaction while the N-terminal and Cterminal domains extend, presumably exposing the binding regions of the protein.
4

Tau also undergoes a variety of post translation modifications (PTMs) that affect
its function within neurons. The most common PTM found on tau is phosphorylation,
with 85 residues available for phosphorylation (35). Phosphorylation levels of tau are
thought to help tau’s native function of regulating microtubule dynamics and
hyperphosphorylation is often thought to be one of the causes for the loss of function of
tau leading to aggregation (28,36). In addition, tau can also undergo acetylation,
methylation, glycation, SUMOylation (36,37). Most of the PTMs are found in the PRR
and MTBR, but some are can also be found in the N-terminal domain of tau.
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Figure 1-1. Tau Schematic. The longest isoform of tau, 2N4R, is shown.
Regions of interest indicated are the N-terminal domain, the proline rich region
(PRR), the microtubule binding region (MTBR) and the C-terminal domain. The
residues mutated to cysteine for labeling span these regions of interest and are
indicated in the schematic. Alternative splicing of N1, N2 and R2 (marked with
dashed lines) result in the six isoforms of tau found in human adults.
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2.3 Microtubule Associated Protein Tau
Tau was first identified in 1975 by Weingarten et al. (27) as a heat stable protein
essential for the polymerization of microtubules (38,39). It was suggested to regulate
microtubule assembly, as the presence of tau allowed soluble tubulin dimers to reform
microtubules.
Microtubules, along with actin and intermediate filaments, form the cytoskeleton of
all eukaryotic cells (40). The cytoskeleton maintains cell shape, organizes, and transports
organelles, regulates cell division and replication, and allows for cell movement through
cilia and flagella (41-47). Microtubules are characterized by their dynamic instability in
cells, undergoing constant polymerization and shrinkage. They are composed of soluble
tubulin dimers, a complex of α- and β- tubulin subunits, arranged into linear
protofilaments. 13 protofilaments link up to form a hollow cylindrical microtubule (48).
The rapid polymerization and depolymerization of microtubules, which can occur on the
timescale of seconds to minutes, is thought to be regulated by microtubule associated
proteins (MAPs) (44).
Years of studies of tau have shown that tau regulates microtubule polymerization,
by binding several tubulin dimers to one tau molecule, increasing its local concentration
leading to polymerization (49-51). Tau has roles in the initiation of polymerization and
formation of long labile microtubules, decreasing turnover into shrinking phase, and
decreasing depolymerization (52,53). Additionally, over time other functions of tau have
also been identified including organization of microtubules by acting as a microtubule
spacer (54-57), protecting microtubules from damage and repair (58,59), transport on
7

microtubules (60), activation of MAP kinases (61), actin polymerization (62) and the
regulation of transport in synapses (63,64).
As the name suggests, binding of tau to microtubules and tubulin occurs through
the microtubule binding domain (51). However, there has also been evidence to show the
second half of the proline rich region (P2) also plays a role to bind tubulin and nucleate
microtubule polymerization (50,51,65,66). This model of tau binding to tubulin and
microtubules has been show by structural analysis using smFRET and Cryo-EM (14,18).
Meanwhile the N- and C- termini project away from the microtubules to form a “fuzzy
coat” (67) and have been postulated have a regulatory role in the polymerization of
tubulin to microtubules and in microtubule spacing (65).

8

2.4 Tau and neurodegeneration
Neurodegeneration is one of the most prevalent age-related diseases in the world,
with over 50 million people worldwide suffering from a form of dementia (68).
Neurodegenerative diseases result in the degeneration and eventual death of neuronal
cells, particularly in the brain. The most common neurodegenerative disease are caused
by abnormal protein assemblies of amyloid proteins, tau, α-synuclein and transactivation
response DNA binding protein 43 (TDP-43) (69). These abnormal conformations of
protein assemblies consist of secondary structures with β-pleated sheets (69). In forming
these rigid irreversible structures, the proteins undergo a phase transition from soluble to
insoluble protein.
Tauopathies are the common neurodegenerative diseases, characterized by the
presence of aggregated tau. Of these, Alzheimer’s Disease (AD) is the most prevalent,
being the sixth leading cause of death in the United States. AD is characterized by the
deposition of neurofibrillary tangles (NFTs). Other tauopathies include Frontotemporal
lobar degeneration with tau inclusions (FTLD-tau) and chronic traumatic encephalitis
(CTE) (Table 1-1).
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Table 1-1 – List of Tauopathies with tau-based pathology
Aging related tau astrogliopathy
Alzheimer's disease (AD)
Amyotrophic lateral sclerosis/parkinsonism-dementia complex
Anti-IgLON5-related Tauopathy
Argyrophilic grain disease (AGD)
Chronic traumatic encephalopathy (CTE)
Corticobasal degeneration (CBD)
Creutzfeldt-Jakob disease
Diffuse neurofibrillary tangles with calcification*
Down's syndrome
Familial British dementia
Familial Danish dementia
Familial frontotemporal dementia and parkinsonism linked to chromosome 17
Gerstmann-Sträussler-Scheinker disease
Guadeloupean parkinsonism
Globular glial Tauopathy (GGT)
Huntington's disease
Myotonic dystrophy
Niemann-Pick disease, type C
Non-Guamanian motor neuron disease with neurofibrillary tangles
Pantothenate kinase-associated neurodegeneration (PKAN) and neurodegeneration
with brain iron accumulation (NBIA)
Postencephalitic parkinsonism
Pick's disease (PiD)
Primary age related tauopathy
Progressive supranuclear palsy (PSP)
SLC9A6-related parkinsonism
Subacute sclerosing pancecephalitis
Pantothenate kinase-associated neurodegeneration (PKAN) and neurodegeneration
with brain iron accumulation (NBIA)
Tau astrogliopathy
Vacoular Tauopathy
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The precise mechanism by which tau aggregates to form non-soluble structured
fibrillary tangles and result in cell death and disease pathology is not fully understood,
though great headway has been made towards understand some of the possible
mechanisms. Additionally, the question also arises whether disease pathology is a gainof-function of toxic aggregates or a loss-of-function of tau’s native function within
neuronal cells.
One commonly accepted mechanism for the development of tau pathology is that
hyperphosphorylation or the presence of mutations, especially in the KXGS sequence in
the MTBR, leads to the dissociation of tau from the microtubules (70-73). This results in
an increase in free available tau in the cytosol of the cells, which then nucleate, seed
aggregation, leading to the formation of NFTs. One other postulated mechanism of tau
aggregation within neuronal cells is tau undergoes liquid-liquid phase separation to form
an intermediate state before aggregation into irreversible fibrils (74).
Another question which arises is whether fibrils are neurotoxic or protective.
Many studies have provided both evidence for and against the toxic nature of NFTs,
filaments, oligomers, or a monomer form of tau. One model suggests that tau is
sequestered into oligomers, and then NFTs to prevent the neurotoxicity of the monomer
and oligomeric states of tau. However, this protection is counterbalanced by the loss of
tau in the cells carrying out their native function (75,76).
Another area of tau pathology not fully understood is the spread of disease.
Histological analysis shows that pathology starts in one area of the brain and often
spreads over time, and this can be used to determine the stage of disease progression (77).
Mouse models also have shown that tau pathology spreads through the brain, even though
11

it was originally present in one region, either due to injection of tau seeds or transgenic
expression of the P301L mutation that leads to FTDP-17 (78,79). Thus, it appears
unlikely that tau pathology is caused by autonomous events in cells leading to
degeneration and cell death, somehow all triggered at once. It is more likely that tau in its
diseased state, spreads from cell to cell leading to further neurodegeneration. While there
is no consensus on how tau spreads, whether it is monomer tau, oligomers, or fibrils,
there is strong evidence that tau pathology spreads through cell-to-cell propagation (80).
However, even as tau spreads, how does it trigger cell death in new cells? One
proposed mechanism is that tau undergoes self-replicating mechanism as observed in
prion diseases (81,82). In this model, soluble tau undergoes an initial conformational
change which nucleates further aggregation of soluble tau molecules in the vicinity to
form aggregates. This is observed when tau seeds, sonicated purified tau fibrils from
patient brains, are injected into the neuronal cultures or brains of healthy mice that then
undergo the tau aggregation (81,82).
Unfortunately, studying tau aggregation in vitro posed the significant hurdle being
that tau does not spontaneously aggregate in solution. Aggregation of tau has to be
induced by the addition of polyanionic molecules such as heparin (83-87), fatty acid
lipids (88,89), and RNA (90). In vitro aggregation studies have shown that the MTBR
fragment of tau is sufficient for aggregation and may increase the rate of aggregation
(91). The key sequences necessary for the aggregation of tau have also been identified as
275

VQIINK280 (PHF6*) and 306VQIVYK311 (PHF6) (91-93). Prior research from the

Rhoades lab has identified an aggregation prone conformation of tau in the presence of
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the molecular aggregation inducer, heparin sulfate, opening up the N- and C-terminal
domains from the PRR and MTBR (33).
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2.5 Scope of this research
While extensive research has been done on the aggregation of tau, questions on the
molecular mechanism by which tau aggregates and spreads disease pathology remain. In
this thesis, I have contributed to the study of tau’s role in the initiation and progression of
neurodegenerative pathology by characterizing the molecular mechanisms of three events
involving tau in function and dysfunction of neuronal cells:
1. The initiation of aggregation; by characterizing three distinct molecular
mechanisms by which tau undergoes begins the nucleation process of
aggregation (chapter 2).
2. The propagation of monomer tau; by investigating the link between lipid
membrane properties and the different domains of tau (chapter 3)
3. The effects of disease mutations on tau function; by characterizing the effects of
the R5L mutation on tubulin binding and polymerization as a function of its
conformation in solution (chapter 4).
Combining these three studies, we have a slightly better understanding of the
importance specific domains play in both the function and dysfunction of tau and how tau
interacts with other cellular components.

14

3 Chapter 2: Polyphosphate initiates tau aggregation through intraand intermolecular scaffolding
This chapter was adapted from Sanjula P. Wickramasinghe, Hope E. Merens, Justine
Lempart, Ursala Jakob, Elizabeth Rhoades. (2019). Polyphosphate Initiates Tau
Aggregation Through Intra- and Intermolecular Scaffolding. Biophysical Journal. 117(4),
717-728.

* I collected all the data in this chapter except for the 2N3R smFRET data collected by
Hope Merens, and the aggregation assays and EM images of tau fibrils collected by
Justine Lempart.

3.1 Introduction
Neurodegenerative tauopathies are a class of heterogeneous dementias and
movement disorders characterized by abnormal accumulation of the microtubuleassociated protein tau in insoluble fibrillar aggregates (94). Aggregation transforms
soluble, unstructured tau monomers into highly insoluble, b-sheet rich paired helical
filaments and neurofibrillary tangles. While the increase of these insoluble aggregates
and the progression of symptoms of neurodegeneration are linked, the triggers and
mechanisms by which aggregation occurs in the brain are not well characterized.
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Normally, tau binds to and stabilizes microtubules and plays an important role in
the organization of the cytoskeleton of neuronal cells (95). Monomer tau is intrinsically
disordered and remains largely disordered even upon binding to microtubules (96,97). In
vitro, tau is highly soluble and aggregates slowly; polyanionic molecules, such as the
extracellular matrix glycosaminoglycan heparin, arachidonic acid or lipid vesicles are
commonly used to enhance the rate of aggregation (88,89,98). We recently demonstrated
a similar activity for linear chains of anionic phosphates (i.e. polyphosphate, polyP),
which dramatically enhanced the aggregation rates of several amyloidogenic proteins,
including tau (99). PolyPs are present at micromolar concentrations in the cytosol of
mammalian neurons (100,101) where they have the potential to interact with tau under
normal physiological conditions.
Tau aggregation is generally described as nucleation-dependent, with the
nucleating species thought to be an “aggregation-prone” monomer (102). Recent
evidence in support of this model comes from a study which identified monomer tau
derived from heparin-induced aggregates as capable of seeding tau aggregation both in
vitro and in cultured cells (103). A molecular description of the conformational change in
monomer tau that predisposes it towards aggregation is of critical importance to
developing a complete picture of the molecular determinants of aggregation. However,
structural characterization of monomer tau is challenging due to its dynamic, disordered
nature. Nuclear magnetic resonance (NMR), which is capable of generating amino acid
specific structural information (104), requires high protein concentrations that favor rapid
aggregation in the presence of molecular inducers. Work from our lab has established that
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single molecule Förster resonance energy transfer (FRET) is a powerful approach to
characterize conformations of aggregation-prone proteins (33,105).
In this study, we used single molecule FRET and fluorescence correlation
spectroscopy (FCS) to investigate polyP binding to tau. We identified that both the
microtubule binding region (MTBR) and the proline rich region (PRR) (Fig. 1-1) contain
binding sites for polyP. Moreover, we found that longer polyP polymers were more
effective at accelerating tau aggregation than shorter ones. Based on our results, we
propose that polyP can serve both as an intramolecular scaffold, by binding to multiple
sites within a single tau molecule, as well as an intermolecular scaffold, by binding to
multiple tau molecules simultaneously.
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3.2 Results
Functionally, tau can be divided into four major domains (Fig. 1-1). The function
of the N-terminal domain is the least well-understood, although it has been proposed to
regulate binding to microtubules (106) as well as to interact with neuronal membranes
(107). The MTBR binds both microtubules and soluble tubulin (39,53) and forms the
core of paired helical filaments. Binding of tau to microtubules is enhanced by the
regions directly flanking both sides of the MTBR (51,108). Alternate splicing of the
second repeat (R2) in the MTBR gives rise to isoforms with either three (3R) or four (4R)
repeat regions and either zero (0N), one (1N) or two (2N) N-terminal inserts (Fig. 1-1)
(31). The 3R and 4R isoforms have different binding affinities (109) and assembly
activities (110) for microtubules. One of the two hexapeptide sequences that play a
crucial role in tau aggregation is located in R2. Since this region is absent in 3R isoforms,
4R isoforms are generally more aggregation-prone (91,93).
Changes to the conformations of each of the domains caused by polyP binding to
tau were probed with single molecule FRET. For site-specific labeling of tau in these
measurements, cysteine residues were introduced at desired labeling positions in the
2N4R and 2N3R isoforms of tau (Fig. 1-1; details in Materials and Methods). The
labeling positions were chosen to span either the entire protein (C17-C433) or specific
regions (all residue numbering throughout is based on the 2N4R isoform): the N-terminal
domain (C17-C149); PRR and MTBR (C149-C372); or the C-terminal domain (C372C433). The donor and acceptor fluorophores were Alexa Fluor 488 maleimide and Alexa
Fluor 594 maleimide, respectively.
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FRET efficiencies (ETeff) from individual photon bursts were calculated as a ratio
of the intensity of the acceptor over the sum of the intensities of the donor and acceptor
(see Materials and Methods for details and correction factors). Higher ETeff values
correspond to shorter distances between the donor and acceptor dyes, whereas lower ETeff
values reflect longer distances. ETeff values were plotted as histograms and fit with a
sum of Gaussian distributions to determine the peak ETeff positions (Fig. 2-1). As an
intrinsically disordered protein, tau populates an ensemble of conformations. For
simplicity and convenience in comparing FRET measurements of different tau constructs
or under different experimental conditions, we use the mean ETeff obtained from fitting to
reflect the average of tau’s conformational ensemble for a given measurement.
Measurements were made in the absence (Fig. 2-1, dashed lines) or presence of polyP300
(average of 300 phosphate units per polymer) (Fig. 2-1, solid lines); polyP concentrations
are given in monomer Pi units.

19

3.2.1 PolyP disrupts long-range intramolecular interactions in tau
In solution, tau is a compact protein despite its length and intrinsic disorder, with
the N- and C- termini in relatively close proximity to the MTBR (33). 2N3R is 31
residues shorter than 2N4R due to the absence of R2; thus, differences in the measured
ETeff between the two isoforms for constructs that span this region, i.e., tauC149-C372
(MTBR and PRR) and tauC17-C433 (entire protein) are expected and observed (Fig. 2-1;
Table 5-2-1). Interestingly, the construct probing the C-terminal domain tauC372-C433,
which is identical in both isoforms, shows a lower ETeff for 2N3R than 2N4R, reflecting a
more extended conformational ensemble for 2N3R. One possible explanation is that
attractive electrostatic interactions between the C-terminal domain and the MTBR are
weakened by the absence of R2.
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Figure 2-1. PolyP disrupts long-range interactions and compacts the PRR and
MTBR of tau. Histograms from smFRET measurements of 2N4R (upper panels and red
fit lines) and 2N3R (lower panels and blue fit lines) tau in the absence (dark gray and
dashed line; left axis) and presence (light gray and solid line; right axis) of 20 µM
polyP300. Labeling positions are chosen to probe the entire protein (C17-C433: a, b); the
N-terminal domain (C17-C149: c, d); the PRR and MTBR (C149-C372: e, f); and the Cterminal domain (C372-C433: g, h). The numbers are the labeling positions by residue
number based on 2N4R. Tau schematics above each histogram represent the isoform and
labeling positions. Measurements carried out in PIE-FRET as described in the Materials
and Methods are marked with an asterisk (dark/light gray in the absence/presence of
polyP) on the top left corner. At least three separate measurements of each
condition/construct were made. The histograms shown are representative. Statistical
analysis of repeat measurements is given in Table 2-1
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labeling

ETeff

ETeff

(buffer)

(+ polyP300)

2N4R

0.15 ± 0.004

0.09 ± 0.004

-0.06 ± 0.006

2N3R

0.18 ± 0.002

0.11 ± 0.006

-0.07 ± 0.006

2N4R

0.40 ± 0.01

0.18 ± 0.003

-0.22 ± 0.010

2N3R

0.40 ± 0.004

0.21 ± 0.005

-0.19 ± 0.006

2N4R

0.17 ± 0.005

0.40 ± 0.002

0.23 ± 0.005

2N3R

0.19 ± 0.002

0.44 ± 0.009

0.25 ± 0.009

2N4R

0.69 ± 0.003

0.50 ± 0.006

-0.19 ± 0.007

2N3R

0.66 ± 0.002

0.46 ± 0.006

-0.20 ± 0.006

construct
positions

∆ETeff

C17-C433

C17-C149

C149-C372

C372-C433

Table 2-1. Mean ETeff values for 2N3R and 2N4R tau in the absence and presence of
20 µM polyP300. Mean ETeff and s.e.m. calculated for a minimum of three measurements
with and without the addition of polyP. ∆ETeff is the difference between tau+polyP300 and
tau. Error of ∆ETeff is calculated by propagation of error as described in the Materials and
Methods. Representative histograms are shown in Fig. 2-2.
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The addition of polyP300 resulted in an increase in the average end-to-end distance
of tau as reflected by the decrease in ETeff for both 2N4R (Fig. 2-1a) and 2N3R (Fig. 21b) tauC17-C433 (Table 2-1). These results suggested that polyP disrupts some of the longrange electrostatic interactions that are responsible for tau’s relatively compact
conformational ensemble in solution. We also noted a similar polyP–mediated population
of lower ETeff values, i.e., larger distances, for both isoforms when the N- and C-terminal
domains were probed independently, using tauC17-C149 or tauC372-C433, respectively (Fig. 21c, d and Fig. 2-1g, h; Table 2-1). In contrast, tauC149-C372, which probes the region
encompassing the PRR and MTBR, showed a relatively large shift to higher ETeff values
for both isoforms, reflecting significant compaction of this region (Fig 2-1e, f; Table 2-1).
Increasing the ionic strength of the buffer solution to 100 and 150 mM KCl eliminated
the observed changes in the ETeff histograms for 2N4R tauC17-C149 and tauC149-C372 at 20
µM polyP300 (Fig. 2-2). However, increasing the concentration of polyP300 to 1 mM
resulting in population of the polyP-bound peak (Fig. 2-2). These data support an
important role for electrostatic interactions in polyP binding to tau. As a whole, these
results are similar to our previous work on tau-heparin interactions (33), suggesting that
there are conserved features in the aggregation-prone conformational ensemble of fulllength monomer tau in the presence of polyanionic aggregation inducers.
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Figure 2-2. ETeff histograms in the presence of polyP and increased KCl. SmFRET
measurements were made for 2N4R tauC17-C149 (a) and tauC149-C372 (b) with 50mM (left
column), 100 mM (middle column) and 150 mM (right column) KCl in the absence of
polyP (top row) and with the addition of 20 µM (middle row) and 1 M polyP300 (bottom
row. While 20 μM polyP causes only small changes in the histograms at higher salt
concentrations, the polyP-bound peak is populated 1 M polyP300 for both 100 mM and
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150 mM KCl An asterisk in the left hand corner of a panel indicates the measurement
was made using PIE-FRET.
3.2.2 PolyP binds to the PRR and MTBR
The MTBR carries an effective net charge of +10.2 and +7.1 at pH 7.4 in the
2N4R and 2N3R isoforms, respectively, while the PRR has a net charge of +13.8. Thus,
our expectation was that the negatively charged polyP binds to these domains and that
changes in the conformational ensembles in other regions of the protein may result from
screening of the positive MTBR and PRR by the anionic polyP. For example, binding of
polyP to the MTBR or PRR may disrupt the long-range interactions with the negatively
charged N-terminal domain, thereby altering its conformational ensemble even if polyP
does not bind directly to the N-terminal domain. To identify the regions of tau involved
in polyP binding, we made six tau fragments (Fig. 2-3): 4R and 3R, which correspond to
the MTBR (residues 244-372) of 2N4R and 2N3R, respectively; P1P2, which is the entire
PRR (residues 148-245); P2-4R and P2-3R, which contain 4R and 3R as well the second
half of the PRR (residues 198-372); and NT, which corresponds to the N-terminal domain
(residues 1-152). The fragments and full-length tau constructs were labeled with a single
fluorophore and fluorescence correlation spectroscopy (FCS) was used to measure their
diffusion times in the absence or presence of polyP14 or polyP300. A change in mass or
hydrodynamic radius of tau upon binding polyP is expected to result in a change in tau’s
diffusion time (Fig. 2-4; details in Materials and Methods). All constructs except for NT
(which showed no change) exhibited an increase in diffusion time ranging from 11 to
24% in the presence of polyP300 relative to the diffusion time of the construct in the
absence of polyP300, indicative of polyP binding (Fig. 2-3; Table 2-2). The two fragments
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lacking R2 in their MTBRs (i.e., P2-3R and 3R), however, reproducibly showed less of
an increase in diffusion time upon binding polyP than their 4R counterparts (i.e., P2-4R
and 4R), suggesting that presence of R2 enhances the interactions with polyP (Fig. 2-3).
Moreover, addition of the shorter polyP14 caused similar increases in the diffusion times
although of smaller magnitudes than observed for polyP300 (Fig. 2-3). Based on these
results, we concluded that polyP binds to both the PRR and MTBR. In addition, the
observed lack of polyP binding to the NT indicated that the large conformational changes
that we observed when we probed the N-terminal domain in the context of the full-length
protein, tauC17-C149 (Fig. 2-1c, d) is not due to direct binding of polyP to this domain but
caused by an overall reconfiguration of tau’s conformational ensemble upon binding of
polyP to the PRR and MTBR.
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Figure 2-3. PolyP binds to the PRR and MTBR. Change in diffusion times of
single labeled tau constructs with the addition of 20 µM polyP300 (solid bars) or
polyP14 (open bars) as measured by FCS. The change is shown as the increase relative
to each construct in the absence of polyP. The results are the average of three separate
measurements, and error bars show s.e.m as described in the Materials and Methods.
The changes in diffusion time between 4R and 3R, and P2-3R and 3R are significant
(p=0.016 and p=0.05 respectively). Statistical analysis of repeat measurements is
given in Table 2-2.
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diffusion time (µs)
buffer

polyP300

polyP14

2N4R

925 M1

1055 ± 5.6

940 ± 3.3

P2-4R

628 ± 8.5

763 ± 3.3

672 ± 5

4R

534 ± 1.0

617 ± 1.0

566 ± 1.2

2N3R

909 ± 12.0

1056 ± 10.2

941 ± 1.3

P2-3R

430 ± 10.0

504 ± 12.7

450 ± 7.0

3R

377 ± 2.5

417 ± 1.4

390 ± 5.3

P1P2

482 ± 4.3

581 ± 2.2

502 ± 11.3

NT

585 ± 0.7

592 ± 8

585 ± 3.0

aSyn*

550

550

Table 2-2. Mean diffusion times of tau constructs in the absence and presence of
polyP300 or polyP14. Mean diffusion time and s.e.m. calculated from three independent
sets of measurements. The percent change in diffusion time with the addition of polyP is
shown in Fig. 2-4. aSyn was only measured once as a control.
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Figure 2-4. Representative autocorrelation curves measured by FCS. Shown are 25
individual autocorrelation curves of 10 seconds each (gray) along with the fit to the
averaged curve (red) for 20 nM 2N4R tau in the absence (a) or presence (b) of 20 μM
polyP300.

29

To understand the relationship between polyP’s binding to the PRR and MTBR
and the conformational changes that we observed by smFRET (Fig. 2-1), we conducted
smFRET measurements focusing on either the MTBR (Fig. 2-5a-c for 4R; Fig. 2-5d-f for
3R) or the PRR (Fig. 2-5g-i) in the context of the full-length constructs or select
fragments. In the absence of polyP, the fragments generally showed higher mean ETeff
values than the full-length proteins, indicating that the flanking regions of the protein
impact the conformational ensembles sampled by the various domains even in solution
(Fig. 2-5, dashed lines; Table 2-3). Full-length tauC244-C372 constructs exhibited a large
shift to higher ETeff upon binding polyP, reflecting a polyP-induced compaction of the
MTBR (Fig. 2-5a, d; Table 2-3). We observed similar results for P2-4RC244-C372 and P23RC244-C372 constructs (Fig. 2-5b, e; Table 2-3), although the magnitudes of the shifts were
not as great as those seen in the full-length proteins. Interestingly, polyP did not cause
any significant shifts in the ETeff values in either of the isolated MTBR fragments, 4RC244C372

or 3RC244-C372 (Fig. 2-5c, f; Fig. 2-4 and Table 2-3) despite clear evidence of binding

to this region as measured by FCS (Fig. 2-3). However, comparison of the ETeff
histograms revealed that binding of polyP to both the full-length tau or the shorter P24RC244-C372 and P2-3RC244-C372 constructs shifts their peak positions close to those of the
isolated MTBR fragments, 4RC244-C372 or 3RC244-C372. These results suggest that the
MTBR fragments in isolation populate a compact monomer conformational ensemble
that is only achieved in the longer tau constructs through binding of polyP. Since isolated
MTBR fragments aggregate more readily than full-length tau (91), our results suggest
that compaction of this domain may play a role, reflecting one mechanism by which
polyP accelerates tau aggregation.
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SmFRET measurements of the other tau fragments were consistent with FCS
measurements that showed binding to P1P2 but not NT. PolyP binding to the isolated
PRR, P1P2C149-C244 caused a shift to higher ETeff (Fig. 2-5i; Table 2-3), although not as
great as seen in full-length tauC149-C244 (Fig. 2-5g, h; Table 2-3). No shift in ETeff was
detected in the isolated N-terminal fragment, NTC17-C149 (Fig. 2-6; Table 2-3).
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Figure 2-5. PolyP binding induces conformational changes in the MTBR when
the PRR is present. Histograms from smFRET measurements probing the MTBR
and PRR in the absence (dark gray and dashed line; left axis) or presence (light gray
and solid line; right axis) of 20 µM polyP300. Histograms for probes of the MTBR
(C244-C372) in 2N4R (a), P2-4R (b), 4R (c), 2N3R (d), P2-3R (e) and 3R (f).
Histograms for probes of the PRR (C149-C244) for 2N4R (g), 2N3R (h) and P1P2 (i).
Tau schematics above each histogram represent the construct and labeling positions.
At least three separate measurements of each condition/construct were made. The
histograms shown are representative. Statistical analysis of repeat measurements is
given in Table 2-3.
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Figure 2-6. PolyP does not cause conformational changes in the MTBR and Nterminal fragments. Histograms measured by smFRET of 4RC244-C372 (a), 3RC244-C372 (b)
and NTC17-C149 (c) in the absence (upper row) and presence of 20 µM (center row) or 40
µM (lower row) polyP300. The higher polyP concentration was tested to determine
whether weak binding occurs in either of these regions. No changes to the histograms are
observed for these fragments even at the higher polyP concentration.
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labeling

ETeff

ETeff

(buffer)

(+ polyP300)

2N4R

0.29 ± 0.008

0.51 ± 0.002

0.22 ± 0.008

P2-4R

0.31 ± 0.002

0.43 ± 0.003

0.12 ± 0.004

4R

0.39 ± 0.004

0.39 ± 0.016

0 ± 0.016

2N3R

0.40 ± 0.002

0.59 ± 0.001

0.19 ± 0.002

P2-3R

0.44 ± 0.006

0.50 ± 0.006

0.07 ± 0.008

3R

0.51 ± 0.006

0.50 ± 0.006

-0.01 ± 0.008

2N4R

0.35 ± 0.005

0.50 ± 0.002

0.15 ± 0.005

2N3R

0.36 ± 0.005

0.54 ± 0.005

0.18 ± 0.007

PRR

0.39 ± 0.006

0.47 ± 0.007

0.07 ± 0.009

2N4R

0.40 ± 0.01

0.18 ± 0.003

-0.22 ± 0.010

2N3R

0.40 ± 0.004

0.21 ± 0.005

-0.19 ± 0.006

NT

0.23 ± 0.014

0.23 ± 0.015

0 ± 0.021

construct
positions

C244-C372

C244-C372

C149-C244

C17-C149

D ETeff

Table 2-3. Mean ETeff for tau constructs in the absence and presence of polyP300.
Mean ETeff and s.e.m calculated for a minimum of three measurements with and without
the addition of polyP. ∆ETeff is the difference between tau+polyP300 and tau. Error of
∆ETeff is calculated by propagation of error as described in the Materials and Methods.
Representative histograms for the different conditions are show in Fig. 2-5 and Fig. 2-6.
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3.2.3 PolyP enhances tau aggregation through intermolecular cross-linking
In vivo, polyP exists as a broad range of polymer lengths (101) and our prior work
with polyP revealed that longer chains are generally more effective at accelerating
aggregation of amyloidogenic proteins than shorter ones (99). Tighter binding may be
important to initiation of aggregation, as tau binds with higher affinity to polyP300 than
polyP60 (Fig. 2-8). To examine whether a relationship exists between polyP chain length,
changes to the conformational ensemble of the monomer protein and aggregation
propensity, we conducted smFRET measurements on select full-length 2N4R constructs,
tauC17-C149 (Fig. 2-7a) and tauC149-C372 (Fig. 2-7b) in the presence of 20 μM polyP14,
polyP60, polyP130 or polyP300 (Table 2-4). In the presence of polyP14, tauC149-C372
underwent a very small increase in ETeff while the tauC17-C149 conformation appeared to
be unchanged (Fig. 2-7; Table 2-4). This was despite the fact that polyP14 binds to both
the full-length protein as well as to the isolated fragments (Fig. 2-3). All other polyP
chain lengths caused large shifts in the mean ETeff for both tauC17-C149 and tauC149-C372 to
the previously observed lower and higher values, respectively (Fig. 2-7; Table 2-4). This
suggests that for longer polyP polymers, a single chain may be able to bind to multiple
binding sites on tau to allow for intra-molecular scaffolding resulting in a change in its
conformational ensemble. When the chain is not long enough (i.e. polyP14) this effect is
not observed.
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Figure 2-7. Tau conformational changes are dependent upon polyP chain length.
Histograms from smFRET measurements probing two different regions of 2N4R, the
N-terminal domain (C17-C149) (a) and the PRR and MTBR (C149-C372) (b) in the
absence or presence of 20 µM polyP of different chain lengths. At least three separate
measurements of each condition/construct were made. The histograms shown are
representative. PIE-FRET was used for tauC17-C149 with 20 µM polyP300 (*). Statistical
analysis of repeat measurements is given in Table 2-4.
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labeling

ETeff

positions

(buffer)

ETeff
polyP

C17-C149

D ETeff

(+polyP)
polyP300

0.18 ± 0.003

-0.22 ± 0.010

0.40 ±

polyP130

0.20 ± 0.004

-0.20 ± 0.011

0.01

polyP60

0.23 ± 0.009

-0.17 ± 0.013

polyP14

0.40 ± 0.013

0 ± 0.016

polyP300

0.40 ± 0.001

0.23 ± 0.005

0.17 ±

polyP130

0.40 ± 0.004

0.23 ± 0.006

0.005

polyP60

0.48 ± 0.01

0.35 ± 0.011

polyP14

0.18 ± 0.029

0.01 ± 0.029

C149-C372

Table 2-4. Mean ETeff of 2N4R tau in the absence and presence of different chain
lengths of polyP. Mean ETeff and s.e.m. calculated for a minimum of three measurements
with and without the addition of polyP. ∆ETeff is the difference between tau+polyP and
tau. Error of ∆ETeff is calculated by propagation of error as described in the Materials and
Methods. Representative histograms are shown in in Fig 2-7.
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Figure 2-8. ETeff histograms as a function of polyP concentration. SmFRET
measurements were made for 2N4R tauC149-C372 with polyP300 (a) or polyP60 (b), tauC17-C149
with polyP300 (c) and 2N3R tauC149-C372 with polyP300 (d). PolyP concentrations ranged
from 0 (top row) to 30 μM (bottom row). All histograms converged to single peaks
before or at 20 μM polyP and no significant shifts in ETeff were observed at higher
concentrations of polyP. For calculation of binding curves, the center for the bound and
unbound peaks were determined at limiting concentrations and fixed for intermediate
concentrations when possible. Note that at high polyP concentrations (i.e. 20 μM) the
polyP-bound peak is shifted from the polyP-bound peak at lower polyp concentrations
(i.e. 20 μM). This likely reflects low affinity interactions between tau and polyP, as seen
previously with heparin. The fraction of tau with polyP-bound (e) is calculated as the area
of the bound peak over the total area of the bound and unbound peaks. These curves are
fit with a hyperbolic binding equation to yield approximate KD’s for polyP300 (~0.4 μM
monomer or 1.3 nM chain) and polyP60 (.~2 μM or 33 nM chain). An asterisk in the left
hand corner of a panel indicates the measurement was made using PIE-FRET.
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Ensemble aggregation experiments were carried out for tau fragments in the
presence of various chain lengths of polyP, resulting in characteristic fibrillar aggregates
(Fig. 2-9). Aggregation was monitored by an increase in Thioflavin T fluorescence and
quantified by the T1/2, the time to reach half the signal plateau (Fig. 2-10; Table 2-5;
details in Materials and Methods). While an inverse relationship between the T1/2 and the
length of polyP was observed for both 3R and 4R, all polyP chain lengths were more
effective at inducing aggregation than heparin (Fig. 2-10). To illustrate, while the T1/2 of
4R was greater than 15 hours in the presence of heparin, it was less than 6 hours in the
presence of polyP14 and less than 10 minutes in the presence of polyP300. Consistent with
previous findings that the 4R-fragment of tau is generally more aggregation-prone than
the 3R-fragment (83) (e.g., T1/2 of 15 hours for 4R versus 60 hours for 3R in the presence
of heparin), the influence of all polyP chains was accordingly less pronounced for the 3Rfragment. Moreover, while polyP was effective in accelerating the aggregation of the two
4R constructs (R4 and P2-R4), it was less effective at inducing aggregation of 3R as
compared to P2-3R (Fig. 2-10; Table 2-5). These data, along with the binding data shown
in Fig. 2-4, support the importance of polyP binding to both R2 and the PRR for effective
acceleration of aggregation; constructs which contain either P2 (i.e., P2-3R), R2 (i.e, 4R)
or both (i.e., P2-4R) aggregate significantly faster in the presence of polyP than 3R,
which lacks both binding sites.
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Figure 2-9. TEM images of tau-polyP fibers. Images of P2-4R with polyP300 (a) and 4R
with polyP300 (b), polyP14 (c) and heparin (d).
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Our smFRET and aggregation data support the conclusion that binding of polyP
to multiple intramolecular sites increases the efficacy of polyP in initiating tau
aggregation. Moreover, our finding that longer polyP chains are more effective in
stimulating tau aggregation suggest that longer polyP chains are able to interact with
several tau monomers, thereby serving as an intermolecular scaffold to non-covalently
cross-link tau monomers. FCS and smFRET measurements are typically carried out at
pM to nM protein concentrations, which strongly disfavor intermolecular protein
interactions. To directly test whether polyP is able to non-covalently cross-link tau
monomers, we conducted FCS measurements at concentrations of 4R and polyP that are
comparable to our ensemble aggregation experiments. The addition of 25 µM unlabeled
4R to 20 nM labeled 4R did not result in a change in its diffusion time, indicating that
tau-tau interactions are not favored at the increased protein concentration in the absence
of polyP (Fig. 2-11a and b). With the addition of 1 mM polyP300, however, extremely
heterogeneous autocorrelation curves were recorded, suggesting the formation of large
oligomeric tau assemblies or aggregates (Fig. 2-10f) (88). These measurements clearly
indicate multiple polyP binding sites in tau, also supported by the FCS measurements
shown in Fig. 2-4, as only a single binding site would results in uniformly bright species
not give rise to heterogenous autocorrelation curves (111). In contrast, the addition of 1
mM polyP14 resulted in only a few aberrant autocorrelation curves, reflecting fewer large
species (Fig. 2-10g). These results suggest that longer polyP chains enhance
intermolecular tau-tau interactions, which might play an important role in the acceleration
of tau aggregation.
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Figure 2-10. PolyP accelerates tau aggregation in a chain length dependent manner.
The aggregation half-times (T1/2) of tau fragments (a) measured by ThT fluorescence
comparing polyP chain lengths and heparin for 4R (b) and 3R (c) and comparing different
fragments for polyP300 (d) and polyP14 (e). Autocorrelation curves of 4R in the presence
of 1 mM polyP300 (f) or polyP14 (g). The individual autocorrelation curves are shown in
gray and the average is in orange. Statistical analysis of repeat measurements for the ThT
fluorescence assays is given in Table 2-5.
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T1/2 (h)
construct

polyP300

polyP130

polyP60

polyP14

heparin

4R

0.4 ± 0.04

1.2 ± 0.07

3.4 ± 0.11

6.6 ± 0.51

15.5 ± 1.74

3R

4.3 ± 1.26

6.8 ± 1.07

30.3 ± 3.95

44.1 ± 3.2

67.2 ± 4.63

T1/2 (h)
construct

P2-4R

P2-3R

4R

3R

polyP300

0.3 ± 0.12

1.0 ± 0.32*

0.4 ± 0.03*

4.3 ± 0.80*

polyP14

8.0 ± 0.65

25.1 ± 2.33

7.2 ± 0.35

42.3 ± 2.32

Table 2-5. Aggregation half-times (T1/2). Mean T1/2 and s.e.m. from ensemble
experiments using ThT fluorescence to follow aggregation kinetics. For the polyP300 data,
differences in the T1/2 of 3R as compared to 4R, P2-3R and P2-4R are statistically
significant (denoted by *) with p-values of 0.0007, 0.004 and 0.003 respectively. Table
contains T1/2 times shown in Fig 2-10.
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Figure 2-11. PolyP is required for crosslinking of tau. Autocorrelation curves of 20
nM labeled 4R in the absence (a) or presence (b) of 25 µM unlabeled 4R or (c) 25 µM
unlabeled 4R and 18 µM heparin. Fits of the averaged curves yield comparable diffusion
times, despite the 1000x difference in tau concentration.
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3.2.5 PolyP is more effective at accelerating tau aggregation than heparin
Heparin is the most commonly used inducer of tau aggregation in vitro (98). To
investigate whether heparin and polyP trigger similar changes in the conformational
ensemble of tau, we compared their effects on tau in smFRET experiments. We measured
two 2N4R constructs, tauC17-C149 and tauC149-C372, using concentrations of heparin (MW
~17,000g) of 130 nM and 1.75 µM, which have the same equivalent charge as ~5 µM and
80 µM polyP, respectively. At these concentrations, heparin induced shifts in the mean
ETeff in the same direction as polyP, although the magnitude of the shift was reproducibly
smaller (Fig. 2-12; Table 2-6). Moreover, heparin does not appear to be as good a
scaffold for binding multiple tau monomers (Fig. 2-10c), as polyP300 and heparin-induced
aggregation of tau displayed a significantly slower kinetics than measured in the presence
of polyP (Fig. 2-10b and c). Together, these data demonstrate that compared to heparin,
polyP is significantly more effective at i) populating a more compact, aggregation-prone
conformational ensemble of tau, ii) cross-linking multiple tau monomers, and
consequently iii) inducing tau aggregation.
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Figure 2-12. Heparin binding causes a smaller conformational change than polyP.
Histograms from smFRET measurements probing two different regions of 2N4R, the Nterminal domain (C17-C149) (a) and the PRR and MTBR (C149-C372) (b) in the
absence or presence of 130 nM or 1.75 µM heparin. The dotted black lines indicate the
average ETeff of the construct with 20 µM polyP300. At least three separate measurements
of each condition and construct were made. The histograms shown are representative.
Statistical analysis of repeat measurements is given in Table 2-6.
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labeling

ETeff

positions

(buffer)

ETeff
heparin ( µM)

C17-C149

ΔETeff
(+ heparin)

0.13

0.24 ± 0.003

-0.16 ± 0.010

1.75

0.24 ± 0.003

-0.16 ± 0.010

0.13

0.36 ± 0.001

0.19 ± 0.005

1.75

0.35 ± 0.006

0.18 ± 0.008

0.40 ± 0.01

C149-C372 0.17 ± 0.005

Table 2-6. Mean ETeff of 2N4R tau in the absence and presence of heparin. Mean
ETeff and s.e.m. calculated for a minimum of three measurements without and with the
addition of heparin. ∆ETeff is the difference between tau+heparin and tau. Error of ∆ETeff
is calculated by propagation of error as described in the Materials and Methods.
Representative histograms are shown in Fig 2-12.

48

3.2.7 PolyP competes with tubulin for tau binding
In vitro, polyP binds to tau and accelerates its aggregation. In neurons, there are
many other biomolecules that can compete with polyP for binding to tau. The most
relevant of these is tubulin, tau’s primary cellular binding partner. We therefore decided
to investigate whether polyP is a competitive binding partner of tau that is capable of
affecting tau’s ability to interact with tubulin in vitro. For these experiments, we used the
P2-4R fragment, which undergoes conformational changes (Fig. 2-5) and aggregates
readily (Fig. 2-10) upon binding polyP and is known to interact with both soluble tubulin
(112) and microtubules (50) in vitro. As a reporter for tubulin binding, we measured the
diffusion time of fluorescently labeled P2-4R in the absence and presence of 5 µM
tubulin by FCS (Fig. 2-13; Fig. 2-14). Consistent with our previous work, binding of P24R to tubulin resulted in an increase in the diffusion time from ~0.66 ms to ~0.93 ms
(111). Upon titration with polyP300, we observed a polyP concentration-dependent
decrease in the diffusion time, reflecting competitive displacement of tubulin from P2-4R
by polyP (Fig. 2-13). In the presence of 100 µM polyP300, the diffusion time of P2-4R
was comparable to that measured for P2-4R with saturating concentrations of polyP in
the absence of tubulin (Fig. 2-3), suggesting that polyP had effectively replaced all of the
bound tubulin.
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Figure 2-13. PolyP competes with tubulin for tau binding. FCS measurements of
tubulin-bound P2-4R in the absence or presence of increasing concentrations of
polyP300. For reference, the dashed lines correspond to the diffusion times measured
for: P2-4R with 5 µM tubulin (upper), P2-4R with 20 µM polyP300 (middle) and P24R in buffer (lower). Data points are the mean and s.e.m of three independent
measurements. Statistical analysis of repeat measurements is given in Table 2-7.
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Figure 2-14. Autocorrelation curves of P2-4R with tubulin and polyP300.
Autocorrelation curves of P2-4R and 5 µM tubulin in the absence (a) or presence (b) of
100 µM polyP300.
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+ 5µM tublin

polyP (µM)
0
100
0
5
10
20
40
100

diffusion time (µs)
0.656 ± 0.035
0.777 ± 0.006
0.934 ± 0.008
0.883 ± 0.065
0.833 ± 0.032
0.828 ± 0.026
0.792 ± 0.023
0.783 ± 0.048

Table 2-7. PolyP competes with tubulin for tau binding. Mean diffusion time and
s.e.m. calculated for a minimum of three measurements with and without the addition of
polyP300 and 5µM tubulin.

52

3.3 Discussion
Our results identified three aspects of the interaction between tau and polyP
relevant to its mechanism of enhancing tau aggregation: (1) binding of polyP to tau’s
MTBR and PRR regions, which changes the conformational ensemble of monomer tau
by causing compaction of those domains; (2) screening of electrostatic interactions
between tau domains and disruption of long-range interactions between tau’s termini and
MTBR; and (3) facilitating intermolecular association of tau monomers (Fig. 2-15).
SmFRET measurements of full-length tau constructs most clearly illustrated that
polyP binding causes both local (compaction of the PRR and MTBR) and long-range
(loss of interaction between the termini and central region) changes in tau’s
conformational ensembles (Fig. 2-1). We found that polyP binds to both PRR and MTBR
regions, yet compaction of the MTBR domain is only observed in the presence of the
PRR (compare Fig. 2-5b and c). We reason that the observed changes in the
conformational ensemble result from the noncovalent intramolecular cross-linking of
binding sites in the PRR and MTBR by a single polyP chain (Fig. 2-15). Upon
occupation of all possible binding sites on tau, no further changes in conformation are
observed. Further evidence in support of this idea came from the use of polyP of different
chain lengths. Even at saturating concentrations, we found that polyP14, which is too short
to span between binding sites in the PRR and MTBR (113), caused only a slight shift in
the mean ETeff of full-length tau (Fig. 2-7) while longer chain lengths (polyP60, polyP130
and polyP300) caused much larger shifts. Interestingly, the shift caused by polyP60 is to a
higher mean ETeff value than that of polyP130 and polyP300 for tauC149-C372 (Fig. 2-7b). The
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shorter end-to-end distance of polyP60 may not be able to span between binding sites
without imposing a more compact conformational ensemble on tau. This effect is likely
only seen for the tauC149-C372 construct (Fig. 2-7b) but not tauC17-C149 (Fig. 2-7a) because
only the probes for the former encompass the PRR and MTBR binding sites.
We consider that both charge screening and intermolecular cross-linking are
likely relevant to the general capability of polyP to accelerate tau aggregation. The tau
fragments are highly positively charged, disfavoring intermolecular interactions in
solution. Indeed, FCS measurements with high concentrations of unlabeled monomer 4R
show no evidence of tau assembly under our solution conditions (Fig. 2-11). Binding of
negatively charged polyP decreases the electrostatic repulsion between monomers so that
intermolecular interactions become more favorable and binding of polyP to tau is
effectively blocked by increasing the buffer ionic strength (Fig. 2-2). While all polyP
chain lengths are capable of accelerating aggregation through this mechanism (Fig. 2-5b),
longer polyPs are more effective because they are also capable of facilitating binding to
multiple tau monomers, increasing their local concentration (Fig. 2-5f, g and Fig. 2-15).
The fact that polyP results in the most rapid acceleration of aggregation of tau fragments
that contain both P2, in the PRR, and R2, in the MTBR suggests that the presence of
additional binding sites may facilitate intermolecular scaffolding by polyP.
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Figure 2-15. Proposed model of polyphosphate induced tau aggregation. The
binding of polyP results in large conformational changes in monomer tau, charge
screening and cross-linking between monomers. These combined effects result in the
acceleration of tau aggregation. Tau domains are colored as: N-terminal domain
(green), PRR (red), MTBR (blue) and C-terminal domain (yellow). PolyP is shown in
black.
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One challenge faced by in vitro aggregation studies is translating their results to a
more physiological context. For example, while disease models generally describe
alterations to tau (such as mutations found in tauopathies) as enhancing the aggregation
propensity of tau, the effects in vitro are usually fairly moderate (94,114). Natively, tau is
associated with either microtubules (27,50) or soluble tubulin (115), although this
interaction is likely to be highly dynamic (51,53). We find that in vitro polyP is able to
displace tubulin from tau (Fig. 2-13) at concentrations much lower than the reported
cytosolic concentrations of polyP (116). However, the cellular cytoplasm is much more
complex than the tertiary mixture explored here and, in addition to tubulin and polyP,
there may be other charged molecules which compete for binding with tau. Thus, while
we cannot extrapolate directly from our in vitro data to the cellular cytoplasm, our
measurements suggest that polyP is capable of binding tau in the presence of tubulin or
microtubules. Moreover, under pathological conditions where tau binding to
microtubules is compromised by mutation or hyperphosphorylation (117), the
cytoplasmic pool of tau available to interact with polyP is increased. Future studies will
investigate whether tubulin-dissociated, polyP-bound monomer might be putative target
for therapeutics (reviewed in (118)). Our results here provide insight into the
conformational features of this monomer and may eventually aid in the design of
therapeutics to combat tauopathies.
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4 Chapter 3: Propagation of tau through interactions with the lipid
membrane is domain-dependent
4.1 Introduction
The spread of tau aggregates in disease pathology and the presence of aggregates in
extracellular spaces suggests that there is cell-to-cell propagation of tau (80). However,
the mechanism of tau uptake and its subsequent release into the cytosol is not fully
understood. There is no consensus within the field about the minimal unit of uptake into
neuronal cells. Some studies have shown that monomer and aggregated tau can be taken
up by neuronal cells by a variety of endocytic pathways (119), while others show that tau
can only be taken up in its aggregated form (120,121).
In attempts to understand tau propagation, several mechanisms of entry for tau
have been proposed:
•

Tau is taken up by endocytosis in its aggregated form (120-122) and an oligomer
composed of a tau trimer is the minimal form of uptake. This uptake mechanism is
mediated by interaction with heparin sulphate proteoglycans (HSPGs) on outer
membrane of the cells (123-125).

•

Monomeric tau has been shown to be taken up by clathirin-mediated endocytosis
(119), which is consistent with results showing that tau interacts with low-density
lipoprotein receptor related protein 1 (LRP1) that is found in cholesterol rich domains
of the cell membrane (126).
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•

Tau can also pass through the membrane through lipid raft dependent endocytosis – a
type of endocytosis independent of clathirin-mediated endocytosis, but sensitive to
cholesterol levels of the membrane (127). Tau passes through the membrane more
readily when the lipid membrane is more ordered with a higher proportion of
cholesterol in the membrane composition (128).
However, there are several caveats to the studies mentioned above. The uptake of

tau through interaction with HSPGs was done with aggregated fragments consisting of
only the microtubule binding domain (124) and the uptake of monomeric tau was studied
with a disease mutation not always found in all disease pathologies (119). And the results
are further dependent on the treatment of the tau fibrils to generate seeds that propagate
between cells (129). While these studies help towards understanding the propagation of
tau from cell-to-cell, it does not provide an accurate description of the full picture of tau
propagation.
In this study, we investigated the role of the individual domains of tau in the
interaction with the cell membrane and the effects of the composition of the membrane
on these interactions. We used a variety of approaches including fluorescent imaging of
live cells and lipid vesicles, and fluorescence correlation spectroscopy of tau with model
membrane vesicles. We identified a possible role of the proline rich region of tau driving
the translocation of tau through the membrane (Fig. 3-1 to 3-3). We also showed that the
interaction of tau may be dependent on both the liquid-ordered state of the membrane and
the charge of the membrane (Fig. 3-4 to 3-6).
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4.2 Results
Tau interaction to the membrane has been described to occur through the Nterminal domain (107), further linked with the N-terminal domain’s possible function as a
microtubule spacer (54) and anchor to the membrane (107). Additionally, interactions to
the membrane have also been mapped though amphipathic helices in the microtubule
binding region (130). The MTBR is most studied for its role in microtubule binding and
as containing the sequences necessary for aggregation, however additional roles of the
other domains, namely the PRR, often get overlooked in its role in the function of tau.
The composition of the lipid raft also must be taken into consideration when
studying interactions between the membrane and cytosolic proteins. The lipid raft model
of the membrane suggest that membrane can form domains within the membrane,
mediated by the proportion of cholesterol and sphingolipids within the domains (131).
Lipid rafts have a higher percentage of cholesterol and have liquid-ordered phase
properties while lower cholesterol levels give liquid-disordered phase like properties.
Additionally, membrane proteins tend to localize to the lipid rafts (132) and could
potentially play a role in diffusion through the membrane.
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4.2.1 Monomer tau is taken up by SH-SY5Y cells
We conducted uptake assays of Alexa-Flour 488 labeled monomer tau with SHSY5Y cells. SH-SY5Y cells are a human neuroblastoma cell line commonly used as a
model for studying neurodegenerative disease. We used several different constructs of
tau; full length tau (2N4R), fragment of the proline rich region and the microtubule
binding region (P1P2-4R), fragment of the proline rich region (P1P2), and a fragment of
the microtubule binding region with all 4 repeats (4R). The proteins were purified and
labeled as described in Materials and Methods. We plated cells on poly-lysine (PLL)
coated glass chambers and incubated the cells with 200 nM of fluorescently labeled tau
monomers. When the cells were ready to be imaged, the media was removed, and
replaced with new media. Qualitative analysis of images (Fig. 3-1) shows that there is
fluorescence within the cells at 6, 12, and 24 hours after the protein is added to the cell
culture media. Fluorescence intensity or number of puncta doesn’t appear to increase
significantly over the 6-to-12-hour timespan suggesting monomer tau, both in its full
length and fragmented forms, is taken up by cultured neuronal cells within the first six
hours.
Upon further analysis of the images, the patterning of fluorescence appears to be
different for P1P2 compared to 2N4R, P1P2-4R, and 4R. The fluorescence patterns from
the cells with P1P2 and P2-4R form a branch-like pattern (Fig. 3-1b and c) while the
2N4R, P1P2-4R and 4R fluorescence appear in the form of distinct puncta (Fig. 3-1a, b
and d). Tau has previously been shown to localize to mitochondria, potentially playing a
role in mitochondrial dysfunction in AD pathology (133). Therefore, we hypothesized
that P1P2 could be localizing to the mitochondria in the SH-SY5Y cells. To investigate
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this, we co-incubated 200 nM of protein with 10 nM of MitoTracker which localizes to
mitochondria in the cell and 10 nM LysoTracker which colocalizes to lysosomal vacuoles
in the cell. P1P2 appears to colocalize with the MitoTracker (Fig. 3-2h) appearing yellow
in the composite image. P1P2-4R and 4R appear to colocalize with the LysoTracker (Fig.
3-2e and o) respectively appearing white.
The difference in fluorescence patterns observed between P1P2 and the other tau
constructs could arise from several different mechanisms. One possibility is that the
mechanism of uptake is different for the proteins, with PRR behaving as a cellpenetrating peptide passively diffusing through the membrane and entering the cytosol
while the other constructs are taken up by an active endocytosis pathway. Another
possibility is that all the constructs are taken up through an endocytosis pathway and are
present in vacuoles in the cells. P1P2 then escapes into the cytosol faster than the
constructs without the proline rich region.
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Figure 3-1. Monomer tau constructs are taken up by SH-SY5Y cells. Fluorescence
images of 200 nM 2N4R (a, e, i), P1P2-4R (b, f, j), P1P2 (c, g, h) and 4R (d, h, k) after 6,
12 or 24 hours of addition to cultured SH-SY5Y cells. Images shown are representative.
Scale bar is 20 µm.
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Figure 3-2. P1P2 colocalizes with mitochondrial markers. Fluorescence images of
uptake of 200 nM (a-e) P1P2-4R, (f - j) P1P2 and (k -o) 4R with 10 nM MitoTracker
(red, b, g, l) and 10 nM LysoTracker (purple, d, I, n). Colocalization is seen in the
composite images of the tau and MitoTracker (yellow colocalization, c, h, m), and tau
and LysoTracker (white colocalization, e, j, o). Images shown are representative. Scale
bar is 20 µm.
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4.2.2 P1P2 is taken up by GPMVs
We looked at the interaction of tau fragments with the isolated cell membranes by
making giant plasma membrane vesicles (GPMVs). These vesicles are isolated from
cultured SH-SY5Y cells as described in the Materials and Methods. The isolated GPMVs
are incubated with 200 nM of Alexa-Fluor 488 labelled P1P2-4R (Fig. 3-3a), P1P2 (Fig.
3-3b) and 4R (Fig. 3-3c) and imaged in PEG-PLL coated Nunc chambers after 1 hour.
P1P2 appears to be encapsulated by the GPMVs (Fig. 3-3b). P1P2-4R shows entry into
the GPMVs (Fig. 3-3a) while the 4R fragment appears to have not bound or entered the
GPMVs at all (Fig. 3-3c). This suggests that the proline rich region of tau could be
interacting with the GPMVs and the fragment passively diffuses through the membrane
leading to the localization of protein within an enclosed vesicle.
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P1P2-4R
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P1P2
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Figure 3-3. The PRR domain appears to enter GPMVs. Fluorescence and DIC
composite images of GMPVs incubated with 200 nM fluorescently labeled (a) P1P2-4R,
(b) P1P2 and (c) 4R imaged after 1 hour. Images shown are representative. Scale bar is
20 µm.
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4.2.3 Tau binds to GUVs
While there appears to be a link between the proline rich region of tau and its
interaction with the plasma membrane, we are unable to identify any features of the
plasma membrane that would influence the interactions. We investigated the interactions
of tau to the lipid components of the plasma membrane by using giant unilamelar vesicles
(GUVs) that do not contain non-lipid components generally found in plasma membranes.
GUVs are a model membrane system with vesicles ranging from 5 to 100 µM and are
used to study macro lipid composition behaviors and can be used to study the interaction
of proteins to membranes with the added ability to control for lipid composition and
charge. GUVs were first made as described in Materials and Methods with 100% 1palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC) with an added .5% 1,2dioleoyl-sn-glycero-3-phosphoethanolamine-N-(lissamine rhodamine B sulfonyl) (18:1
Liss Rhode PE), a fluorescently labeled phospholipid, to visualize the vesicles. The
GUVs were hydrated with 100 mM sucrose and allowed to settle through a 100 mM
glucose solution. 200 nM of fluorescently labeled tau was incubated with the GUVs for 2
hours before imaging the vesicles. P1P2 interacts with 100% POPC vesicles (Fig. 3-4a)
and in some instances appears to have crossed the membrane and been encapsulated by
the GUVs. On the contrary, the 4R fragment does not appear to bind to the 100% POPC
vesicles when imaged under the same conditions (Fig. 3-4c).

66

To investigate the effect of charge on the interactions between the proline rich
region (net charge of +13.8) and the microtubule binding region (net charge of +10.2), we
made vesicles comprised of 50% POPC and 50% 1-palmitoyl-2-oleoyl-sn-glycero-3phospho-L-serine (POPS) which contains a charge of -1 per lipid. Both P1P2 (Fig. 3-4b)
and 4R (Fig. 3-4d) bound to the membrane of these vesicles. Of further interest, P1P2
does not appear to have crossed the membrane when incubated with the vesicles
containing charged lipids.
To study the effect of lipid composition of the vesicles on tau binding, we made
vesicles comprised of liquid ordered (Lo) (Fig. 3-5a) and liquid disordered (Ld) (Fig. 35b) domains. These compositions are achieved by changing the ratio of sphingomyelin
(Brain) (bSM), POPC, and Cholesterol (Chol) in the lipid mixtures (134,135). P1P2 binds
to the neutral membrane and travels through the membrane for both the Lo and Ld
vesicles (Fig. 3-5a and b). We also tested the interaction of P1P2 with vesicles composed
of a mixture of Ld and Lo domains. P1P2 interacts with the vesicles in a similar manner
to the individual Ld and Lo vesicles (Fig. 3-5c). However, when the composition of the
vesicles was changed to contain 15% POPS (replacing a fraction of POPC) and
introducing a negative charge to the vesicles, P1P2 binds to the membrane but does not
travel through the membrane (Fig. 3-5d).
In vesicles of this size, it is possible that there is phase separation of the domains,
resulting in some regions with higher cholesterol compared, so we cannot conclusively
say whether there is an effect of the order of the membrane of tau’s interaction with the
lipid membrane. However, adding a charged component to the membranes prevents
P1P2 from crossing the membrane, and instead keeps it sequestered at the membrane.
67

POPC

.50 POPC/ .50 POPS

a

b

c

d

P1P2

4R

Figure 3-4. P1P2 and 4R interact with GUVs. 200nM of fluorescently labeled (a, b)
P1P2 and (c, d) 4R (green) are incubated with GUVs made of (a, c) 100% POPC or 50%
POPC and 50% POPS (b, d) with 0.5% of added 18:1 Liss-Rhod PE (red). White solid
boxes highlight GUVs with enclosed tau and white dashed boxes highlight tau bound to
the membrane. Scale bar is 30 µm. Images shown are representative.
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Figure 3-5. P1P2 interacts with membranes with different lipid compositions.
Confocal images of fluorescently labeled P1P2 (green) with (a) liquid ordered
(bSM/POPC/Chol - 10/80/10) (b) liquid disordered (bSM/POPC/Chol – 30/50/20) (c) a
mixture of liquid ordered and liquid disordered domains (bSM/POPC/Chol – 39/39/22)
and (d) a mixture of liquid ordered and liquid disordered domains with added negative
charge from POPS (bSM/POPC+POPS/Chol – 39/39/22). The GUVs were made with
added .5% Liss Rhod DPE (red). White solid boxes highlight GUVs with enclosed tau
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and white dashed boxes highlight tau bound to the membrane. Scale bar is 30 µm. Images
shown are representative.
4.2.4 Tau binds to LUVs
To further investigate the link between domain dependence of tau and we tested
the binding of the tau to large unilamelar vesicles (LUVs), 70-100 nm in diameter. We
conducted FCS measurements with several different fragments of tau and calculated the
fraction of fluorescently labeled tau bound to lipid vesicles (as described in Materials and
Methods). We looked at the binding of full-length tau (2N4R), the proline rich region and
microtubule binding region (P1P2-4R-R’), the second half of PRR and the MTBR (P24R), and the N-terminal fragment (NT) to LUVs made of 50% POPC and 50% POPS.
2N4R reached full saturation at 10 µM, with P1P2-4R-R’ and P2-4R reaching full
saturation at 100 µM (Fig. 3-6a). However, the N-terminal fragment did not bind, even at
concentrations of LUVs as high as 750 µM. Similarly, when we tested the binding of taut
o LUVs made with bSM, POPC, and Chol at a ratio resulting in a mixture of Lo and Ld
domains (Fig 3-6h), we saw weaker binding with 2N4R only reaching full saturation at
1mM LUVs (Fig. 3-6b). However, like with the POPC/POPC vesicles, the N-terminal
fragment did not show any binding.
The N-terminal fragment did not exhibit any signs of binding to model lipid
membranes, while the proline rich region and microtubule binding region showed strong
binding Therefore, we decided to focus on the binding of the proline rich region (P1P2)
and the microtubule binding domain (4R) to LUVs, and how membrane composition
could affect this binding. Comparing LUVs made with a majority Ld domains (low
cholesterol) (Fig. 3-6b) and Ld domains (Fig. 3-6d), both P1P2 and 4R show weak
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binding to the Ld vesicles, only reaching about 10% fraction bound at 1mM LUVs. Both
fragments show higher binding to the Lo vesicles, reaching full saturation at 1mM LUVs,
with P1P2 reaching full saturation and 4R plateauing at approximately 80% fraction
bound.
We then made Lo and Ld vesicles with added negative charge by including 15%
POPS of the total lipid composition, by replacing a fraction of the POPC in the
composition. This negative charge reflects the negative charge found in the cell
membrane (136). Both P1P2 and 4R showed higher binding to the Ld LUVs compared to
vesicles with no added negative charge, reaching full saturation at ~7.5 mM vesicles (Fig.
3-6e). However, the binding to Lo vesicles decreased in comparison to neutral vesicles
(Fig. 3-6f). P1P2 and 4R bind to Ld and Lo vesicles with similar affinities. It appears that
neutral Lo vesicles have the tightest binding to P1P2, followed by charged Ld and Lo
lipid vesicles which have very similar binding curves, with neutral Ld vesicles having the
weakest binding. Lipid vesicles made with 85% POPC and 15% POPS (Fig. 3-6g) also
show relatively weak binding to P1P2 and 4R. Thus, a combination of order in the
vesicles provided by the addition of bSM and Chol, plus negative charge for increased
interaction with the positively charged tau fragments, allows for tightest binding.
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Figure 3-6. Tau binds to LUVs. Fraction bound calculations from FCS
measurements for fluorescently labeled tau fragments to LUVs. We compare the
difference of tau binding to (a) .50 POPC / .50 POPS vesicles, (b) vesicles with liquid
disordered and liquid ordered domains ( .39 bSM / .39 POPC / .22 Chol), (c) liquid
disordered vesicles ( .10 bSM / .80 POPC / .10 Chol), (d) liquid ordered vesicles (.30
bSM / .20 POPC / .50 Chol), (e) liquid disordered vesicles with added charge (.10 bSM /
.65 POPC / .15 POPS / .10 Chol), (f) liquid ordered vesicles with added charge (.30 bSM
/ .05 POPC / .15 POPS / .50 Chol) and (g) .85 POPC / .15 POPS vesicles. (h) A phase
diagram adapted from Petruzielo et al (137) with compositions for lipid vesicles for
liquid disordered (diamond), liquid ordered (triangle), and liquid disordered and liquid
ordered (star).
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4.3 Discussion
In these experiments we have laid the groundwork to answer some outstanding
questions about the role of the domains of tau in cell-to-cell propagation, and how tau
interacts with the lipid plasma membrane. Previous studies have suggested that tau
interacts with the plasma membrane through its N-terminal domain (107) and there are
conflicting studies pointing to monomer uptake (119) versus the minimal unit required
for tau uptake being tau trimer (122). However, these studies are dependent on the
treatment of the tau fragments and the cell types used, and often are done with just the
microtubule binding domain of tau, and thus leaves out any potential effects of the
proline rich region on tau’s binding to the lipid membrane, and subsequent uptake into
cells. The proline rich region has for the most part been overlooked, despite the proline
rich region playing a role in binding to tubulin (65,66) and its effects on the early stages
of aggregation leading to dysfunction (138).
We first showed that the N-terminal domain (NT) does not bind to lipid
membranes, either a simple POPC/POPS mixture or a more complex model system with
bSM, POPC, and Chol, while full length and fragments with the MTBR and PRR bind to
the lipid membrane vesicles. This suggests that there is no intrinsic interaction between
the negatively charged N-terminal domain and lipids, however this does not discount the
possibility of this domain interacting with membrane bound proteins on the inner- and
outer-leaflets of the cell membrane.
Uptake of monomer tau was observed by SH-SY5Y cells, and the pattern of
fluorescence exhibited by the fragments containing the PRR suggests that the mechanism
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of PRR uptake into cells is different to full length tau or the fragment of just the
microtubule binding region (Fig. 3-6 and 3-7). Preliminary imaging studies suggested
that in the time frame that we were observing the cells, P1P2 was in the cytosol of the
cells and potentially localizing with the mitochondria, whereas the other fragments were
localized to vacuoles, most likely in the endosomes. This presented two possible
mechanisms of uptake: i) Tau was taken up by endocytosis, and P1P2 escaped the
vacuoles and entered the cytosol or, ii) Tau was taken up by endocytosis, while P1P2
diffuses passively through the lipid membrane.
Binding of tau to GPMVs provides further evidence for the possibility of P1P2
translocating across the membrane. These vesicles are derived from neuronal cells and do
not have the capacity for active transport, so if there is any translocation through the
membrane, it would be through passive diffusion. We still observe potential entry of the
fragments containing the PRR, P1P2-4R, and P1P2 into the GPMVs but not 4R (Fig. 33). Thus, we observe a consistent difference between fragments with or without the PRR
suggesting that PRR is able to freely diffuse through the lipid membrane.
Similarly, when we move into a less complex system and observe the interactions
between tau and model membranes, we observe tau entering GUVs made of 2-4
component mixtures. P1P2 enters vesicles made of 100% POPC, whereas 4R does not
(Fig. 3-4a and c). However, since we can control for the properties of the membrane, we
introduced negative charge to the system to change the behavior of interaction. As such,
we then observed binding of 4R to the membrane, and P1P2 also bound to the membrane
without passing through (Fig. 3-4b and d). With more complex lipid membranes, forming
liquid ordered and liquid disordered vesicles with the addition of bSM and Chol, P1P2
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bound to the membrane if a negative charge was introduced with POPS (Fig. 3-5d), but
diffused through the membrane if there was no negative charge (Fig. 3-5a-c). This
suggests that the proline rich region can diffuse through the lipid membranes but
interacting with charged lipid molecules prevents it from diffusing through.
We attempted to quantify the binding of tau domains to lipid membranes, and the
effect of charge and order of the domains plays out such that tau binds preferentially to
liquid ordered domains and the presence of liquid ordered domains increases binding
(Fig. 3-6c, d and g) but the presence of negatively charged lipids erases that the
difference between order and disorder in the membrane (Fig. 3-6e and f).
From these studies we have started to outline a possible link between compositional
order of membranes and tau binding. These domains in model membranes mimic the raft
domains high in sphingolipid and cholesterol that have been postulated in plasma
membranes. Membrane proteins also have been found to localize within these domains
(139-142) and serve as the location of endocytosis mechanisms in the cell dependent on
cholesterol levels (143). We can also see that tau binds more tightly to membranes with
more complex organization, with bSM and Chol which form liquid ordered and
disordered domains (135), and the interaction with these ordered lipid membranes occurs
primarily through the proline rich region, aided by the microtubule binding domain.
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4.4 Future Directions
Unfortunately, we ran into several issues of reproducibility while conducting
these experiments. We experienced trouble with tissue culture further hindered by the
Covid-19 lockdown after which we decided to switch to finishing the model membrane
studies first. However, to provide a more robust picture of tau uptake by cells, further
studies can also be conducted in different cell lines which have shown various degrees of
tau uptake (129).
The question of uptake in live SH-SY5Y cells can be studied by shutting down
various endocytosis pathways. Some possibilities of shutting down uptake are i) placing
the cells at 4 C to slow down active processes, so only passive translocation of the
proteins would occur or ii) employing inhibitors such as Dynasore, a dynamin inhibitor
which slows down clathirin mediated endocytosis (119). If P1P2 can passively diffuse
through the membrane, it should still be able to enter the cells when endocytosis
pathways have been shut down.
While the GUV studies were promising, we ran into difficulty in producing a
consistent yield thus affecting the interaction of tau with the vesicles as a result of
variable tau-lipid ratios. To minimize this variability, the sample could be passed through
a density gradient to separate out vesicles of similar sizes, and a phosphate assay carried
out on the fractions before lipid vesicle samples of equal concentrations are taken out
with the same lipid concentrations. However, GUVs production would have to be scaled
up to make this a feasible option. Additionally, the vesicles could be made with a small
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percentage of streptavidin and used to adhere the vesicles to a biotin coated surface, and
then allowing the protein to be flowed in through a flow cell.

5

Chapter 4: The effects of the pathogenic R5L mutation on tau
binding to tubulin

5.1 Introduction
Tau is a microtubule associated protein found in the axons of neurons. It has been
shown to play a role in the polymerization and depolymerization of microtubules (49,50),
acting as a microtubule spacer (54-57), play a role in kinesin and retrograde transport on
microtubules (60), and the repair of damaged of microtubules (51,58,59).
Roughly one hundred mutations have been identified on the MAPT gene that
encodes tau, and of these over 30 have been linked to disease pathology (Alzforum).
Most of the mutations are missense mutations that have varying effects on tau’s ability to
perform its native functions and lead to increased tau aggregation (144). Studies have
shown that most of the mutations show a decrease in microtubule affinity, especially the
mutations that span the proline rich region and the microtubule binding region (71,145).
However, some mutations are exceptions, such as S305N and Q336R, have the opposite
effect and result in increased affinity to microtubules (146,147). Additionally, most of
these mutations seem to result in an increase in aggregation of tau (144,148). As a result
of these observations, a widely accepted model is that the presence of mutations, along
with hyperphosphorylation of tau, leads to decreased microtubule affinity. This gives rise
to more free tau in the cytosol resulting in increased tau aggregation.
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Most of the mutations are present in the proline rich region and the microtubule
binding domain. However, several mutations are found in disease pathology occur in the
N-terminal domain of tau. These mutations also show decreased ability to promote
microtubule assembly and increased tau dysfunction. In this study, we focused on the
R5L mutation, found in Progressive Supranuclear Palsy (PSP) (149). This mutation has
previously been shown to decrease microtubule assembly (149,150) while also increasing
aggregation propensity (151). However since the deletion of the N-terminal domains
from tau does not decrease the binding affinity of tau to the microtubules (66), the
mechanism by which this mutation effects tau’s ability to regulate microtubule dynamics
is not well understood.
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5.2 Results
Work done by the Berger lab at the University of Vermont has shown that
consistent with previous results, tau binding affinity to microtubules is not affected by the
presence of the R5L mutation (152). However, local changes in the structure of R5L-Tau
as shown by NMR and dynamic light scattering (DLS) disrupt Tau patch formation on
microtubules. Tau patches arise in a concentration dependent manner on microtubules
and are observed both in vitro and in neuronal cells (60). At lower concentrations, tau
binds to microtubules in a mixture of diffusive and static states, however as the
concentration increases Tau forms larger order patches (60). The presence of the R5L
mutation decreases tau patch formation on microtubules, by shifting tau towards a more
diffusive state and resulting in smaller patches with fewer molecules per patch. This
behavior was specific to the 3R isoform of tau, as some of the differences observed
between WT and the R5L mutation are no longer significant in the 0N4R constructs.
As such, the Berger lab put forth a new model through with the R5L mutation
affects tau function. Instead of a loss of binding affinity, the mutation in the N-terminal
domain affects the formation of tau complexes through intermolecular interactions. As
tau is instrumental to the polymerization mechanisms of tubulin to form microtubules,
and since microtubules are in a constant dynamic state, the interplay between tau binding
to soluble tubulin and microtubules is an important feature of tau’s function. Therefore,
we conducted experiments to compliment this model, by investigating the effects of the
R5L mutation on the interactions of tau with soluble tubulin and the effects of the R5L
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mutation on the conformation of tau in solution, its binding to soluble tubulin, and the
polymerization of soluble tubulin to form microtubules.
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5.2.1 The R5L mutation does not have a significant effect on binding to soluble tubulin
The presence of the R5L mutation on 0N3R tau shows differences in the
occupancy of tau and the formation of tau patches on microtubules, while not showing
much of a difference between tau binding patterns and dwell time on the microtubules at
low concentration (152). However, at higher concentrations R5L tau binds in a diffusive
state to the microtubules and affects the rate of depolymerization of the microtubules. To
study the effect of the R5L mutation on the binding of tau, we measured the diffusion
time of fluorescently labeled tau using fluorescence correlation spectroscopy (FCS) with
increasing concentrations of soluble tubulin dimers. A change in the diffusion time is
expected to correlate with a change in hydrodynamic radius or a change of mass upon
binding to soluble tubulin. We first measured the binding of tau to tubulin of WT 0N3R
(Fig. 4-1a, red crosses) and R5L-0N3R (Fig. 4-1a, blue circles) in BRB80 buffer (80 mM
PIPES, 1 mM MgCl2, 1 mM EGTA, pH 6.8. R5L-0N3R tau has a higher diffusion time
in solution compared to WT-0N3R (Table 4-1a). However, there is no statistically
significant difference between WT and R5L-0N3R the change in diffusion time with the
addition of tubulin (Fig. 4-1c).
We also compared the effect of the R5L mutation on the binding of 0N4R tau to
tubulin (Fig. 4-1b). We do not observe a difference in the diffusion time of tau alone in
solution, and similarly to 0N3R diffusion time we see an increase in the diffusion time of
tau with increasing concentrations of tubulin.
However, since BRB80 is a high molarity buffer that can easily screen charge,
and thus minimize any effects of the mutation on the binding of tau to tubulin, we
repeated the binding measurements in a low salt buffer (20 mM Tris–HCl, pH 7.4,
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50 mM NaCl). Here we observed greater changes in the diffusion time upon binding to
tubulin, an increase of ~ 1 ms in the low salt buffer (Fig. 4-2c and d) vs BRB80 buffer
(Fig. 4-1c and d). Furthermore, the R5L mutation showed statistically significant higher
binding to tubulin in the 0N3R isoform, particular at low concentrations of tubulin (0.5 to
2 µM tubulin). However, there was no difference in binding between the WT and R5L
mutant in the 0N4R isoform (Fig. 4-2b and d).
From these data, while there are slight differences between the 0N3R wildtype
and R5L mutant in a low salt buffer, this difference is non-significant in BRB80 buffer,
the buffer conditions under which differences between the wildtype and R5L mutant
binding to microtubules is observed. As such, any differences observed on the effects of
tau binding to soluble tubulin would be minimal.
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Figure 4-1. Effects of the R5L mutation in BRB80 buffer. FCS binding curves
showing the diffusion time for WT (red circle) and the R5L mutant (blue cross) in (a)
0N3R and (b) 0N4R tau. The change in diffusion time compared to tau alone in solution
are shown for (c) 0N3R and (d) 0N4R tau. Values are shown in Table 4-1.
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Figure 4-2. Effects of the R5L mutation in low salt buffer. FCS binding curves
showing the diffusion time for WT (red circle) and the R5L mutant (blue cross) in (a)
0N3R and (b) 0N4R tau. The change in diffusion time compared to tau alone in solution
are shown for (c) 0N3R and (d) 0N4R tau. Values are shown in Table 4-2.

85

A
tubulin / µM
0.0
0.5
1.0
1.5
2.0
2.5
5.0
7.5
10.0

B
tubulin / µM
0.00
0.25
0.50
0.75
1.00
1.50
2.00
2.50
5.00
7.50
10.00

diffusion time / ms
0N3R

0N4R

WT
R5L
0.589 ± 0.009 0.617 ± 0.012
0.680 ± 0.012 0.698 ± 0.009
0.737 ± 0.015 0.745 ± 0.051
0.741 ± 0.055 0.746 ± 0.062
0.768 ± 0.040 0.794 ± 0.031
0.812 ± 0.016 0.858 ± 0.082
0.778 ± 0.011 0.868 ± 0.081
0.867 ± 0.011 0.950 ± 0.032
0.819 ± 0.012 0.836 ± 0.040

WT
0.854 ± 0.027
0.943 ± 0.030
1.055 ± 0.048
1.098 ± 0.048
1.097 ± 0.085
1.143 ± 0.115
1.206 ± 0.135
1.248 ± 0.041
1.278 ± 0.077

R5L
0.850 ± 0.034
0.930 ± 0.046
1.013 ± 0.005
1.072 ± 0.020
1.181 ± 0.132
1.125 ± 0.073
1.132 ± 0.021
1.152 ± 0.021
1.216 ± 0.039

diffusion time / ms
0N3R
WT
0.589 ± 0.004
0.894 ± 0.016
1.091 ± 0.051
1.105 ± 0.034
1.080 ± 0.050
1.108 ± 0.051
1.324 ± 0.057
1.254 ± 0.098
1.281 ± 0.066
1.408 ± 0.030
1.388 ± 0.032

R5L
0.632 ± 0.018
1.127 ± 0.088
1.260 ± 0.091
1.315 ± 0.074
1.334 ± 0.049
1.435 ± 0.073
1.487 ± 0.145
1.644 ± 0.045
1/535 ± 0.130
1.608 ± 0.043
1.612 ± 0.061

0N4R
WT
0.744 ± 0.016
1.063 ± 0.087
1.211 ± 0.058
1.163 ± 0.049
1.306 ± 0.079
1.430 ± 0.161
1.686 ± 0.251
1.591 ± 0.115
1.760 ± 0.105
1.870 ± 0.125
1.990 ± 0.130

R5L
0.749 ± 0.011
0.986 ± 0.038
1.160 ± 0.171
1.026 ± 0.056
1.258 ± 0.140
1.468 ± 0.237
1.768 ± 0.290
1.646 ± 0.185
1.868 ± 0.261
2.228 ± 0.420
2.177 ± 0.322

Table 4-1. Diffusion times of 0N3R and 0N4R tau. Mean diffusion times and s.e.m
calculated from three sets of independent measurements in BRB80 buffer (A) and low
salt buffer (B). The changes in diffusion time plotted on Fig. 4-1 and 4-2 are calculated
by subtracting the respective diffusion time at 0 µM tubulin from each value.
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5.2.2 No difference in the conformation between WT-tau and R5L-tau.
We observed a difference in the diffusion time of 0N3R wildtype and the R5L
mutant in BRB80 buffer suggesting a difference in hydrodynamic radius of the proteins
(Fig. 4-1a, Table 4-1). While this may not result in a change in the binding affinity to
soluble tubulin, differences in the conformation of tau could result in the mechanism of
binding to microtubules. Since NMR data shows local shifts in structure , (152)we
decided to look at the differences in conformation of tau with and without the R5L
mutation. We made several WT-0N3R (Fig. 4-3, 4-4, upper panel, red) and R5L-0N3R
(Fig. 4-3 and 4-4, lower panel, blue) tau constructs to probe different regions of tau; the
N-terminal domain, 0N3RC17-C149 (Fig, 4-3 and 4-4, a and b), the N-terminal and proline
rich region 0N3RC17-C244 (Fig. 4-3 and 4-4, c and d), and the proline rich region and
microtubule binding domain 0N3RC149-C1372 (Fig. 4-3 and 4-4, e and f).
Measurements done in BRB80 buffer (Fig. 4-3), which showed a difference in
diffusion time with just protein alone in solution (Fig. 4-1, Table 4-1a), did not show a
significant difference in ETeff for any of the domains probed. When the measurements
were repeated in the low salt buffer, there were also no observable differences between
the WT and R5L constructs. However, the 0N3RC17-C244 constructs which probe the Nterminal domain and proline rich region showed a higher ETeff in the low salt buffer
compared to BRB80 buffer, showing a decrease in the distance between the two probes.
The global conformation of tau in solution is such that the N-terminal domain folds over
the PRR and MTBR and likely forms electrostatic interactions (33,34,138). In a higher
molarity buffer (BRB80), this interaction between the N-terminal domain and the PRR
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and MTBR is decreased. This is a possible explanation for the increased binding of tau
to tubulin in the low salt buffer (Fig. 4-2) compared to BRB80 (Fig. 4-1).
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Figure 4-3. The R5L mutant does not have an effect on the conformation of 0N3R
tau in BRB80 buffer. Histograms from smFRET measurements of WT-0N3R (upper
panel) and R5L-0N3R (lower panel). Labeling positions were chosen to cover the Nterminal domain (C17-C149: a, b), the N-terminal domain and the proline rich region
(C17-C244: c, d) and the proline rich region and the microtubule binding region (C149C372: e, f). Measurements were carried out in PIE-FRET.
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Figure 4-4. The R5L mutant does not have an effect on the conformation of 0N3R
tau in low salt buffer. Histograms from smFRET measurements of WT-0N3R (upper
panel) and R5L-0N3R (lower panel). Labeling positions were chosen to cover the Nterminal domain (C17-C149: a, b), the N-terminal domain and the proline rich region
(C17-C244: c, d) and the proline rich region and the microtubule binding region (C149C372: e, f). Measurements were carried out in PIE-FRET except for c and d.

90

A
WT
R5L
B
WT
R5L

C17-C149
0.62
0.63

ETeff
C17-C244
0.4
0.42

C149-C372
0.18
0.18

C17-C149
0.73
0.75

ETeff
C17-C244
0.65
0.63

C149-C372
0.25
0.26

Table 4-2 FRET efficiency values of 0N3R tau. ETeff values of 0N3R tau for three
difference constructs in BRB0 buffer (A) and in low salt buffer (B).
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5.2.3 The R5L mutation doesn’t have a significant effect on the polymerization of
tubulin
The R5L mutation has been shown to have an effect on microtubule dynamics and
kinetics, with the R5L mutation resulting in faster dwell times and faster shrinkage (152).
Therefore, we investigated the effect of the R5L mutation on the polymerization of
soluble tubulin. As tubulin does not polymerize spontaneously below 90 µM (153),
polymerization of low concentrations of tubulin can be initiated by mixing low
concentrations of tubulin with tau at a 2:1 ratio with 1 mM Guanosine-5'-triphosphate
(GTP). Polymerization is recorded as an increase in turbidity of the solution, measured by
light scattering at 340 nm. The normalized kinetic intensity curves show that there is no
difference in the polymerization kinetics of 0N3R tau. R5L 0N4R appears to have a
slightly faster Kd than WT 0N4R tau (Fig. 4-5).
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Figure 4-5. Light scattering polymerization assays. Normalized light scattering kinetic
curves of WT (red) and the R5L mutant (blue) in (a) 0N3R and (b) 0N4R.
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5.3 Discussion
From these results we can, we show that there does not appear to be a significant
difference between the overall binding of WT and R5L tau to soluble tubulin, for either
0N3R or 0N4R. However, in low salt buffers that are less likely to screen any
electrostatic interactions between tau and tubulin, R5L shows higher binding affinity to
tubulin than WT tau (Fig. 3-2a). One suggestion for the role of R5 is forming salt bridges
with either itself or tubulin to form tau-tubulin complexes (154). If R5L-0N3R has a
higher affinity to tubulin at low salt concentrations, it is possible this salt bridge with the
MTBR of tau is disrupted and allows for more binding of tau to tubulin. However, as the
concentration of tau increases, this salt bridge is eventually broken and both reach similar
levels of saturation. As this is also only visible in the 0N3R construct and not the 0N4R
construct, it could be an effect of the regulatory effect that is more pronounced when the
second repeat of the MTBR has been alternately spliced out (14).
From the smFRET data, there is not a significant difference between WT-0N3R
and R5L-0N3R when comparing the N-terminal domain, PRR, and MTBR. However, in
low salt buffers the construct probing the N-terminal and PRR constructs show a higher
FRET efficiency (Fig. 4-4 c and d), therefore a more compact conformation when
compared to the higher salt BRB80 buffer (Fig. 4-3c and d). This change in conformation
to more extended in low salt buffer, may account for the increased binding affinity to
tubulin in low salt buffer (Fig. 4-1 and Fig. 4-2).
Another possible mechanism for the effects of the R5L mutation could be an
intermolecular interaction, with R5L-tau changing the formation of higher order
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complexes of tau-tubulin. While there may not be significant differences between the
rates of polymerization of tubulin with WT and R5L tau, the measurements conducted
thus far do not account for bundling of microtubules as they polymerize, or a
concentration dependent effect of tubulin as the polymerization measurements were
carried out at saturating concentrations of tubulin.
R5L is found in PSP, which is mainly a disorder associated 0N4R and 1N4R tau.
However many of the observations are specific to the 0N3R isoform of tau and not
reproducible in the 0N4R isoform of tau. The presence of the second repeat region plays
a role in the interactions between the N-terminal domain and the microtubule binding
domain of the protein, so the exact mechanism by which the R5L influences disorder of
tau leading to disease pathology has to be further investigated.
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5.4 Future directions
While we haven’t observed any differences in conformation between WT and
R5L tau while probing the N-terminal domain, the N-terminal and PRR, and PRR and
MTBR, it is possible that since we only expect small local changes, these pairs of probes
haven’t been able to pick up on any differences caused by the R5L mutation. We should
probe the end-to-end contacts of tau (C17-C433). And it would also be beneficial to see if
there are any differences, either as a factor of conformation or concentration, on tau
binding to tubulin.
One possible explanation that is consistent with both results from the Berger Lab
and these studies, is that while the R5L mutation doesn’t affect the rate of
polymerization, it may change the bundling of microtubules under macromolecular
crowding conditions which might explain the differences in tau patch formation (54). To
answer this question, we would carry out light scattering polymerization assays with the
addition of molecular crowders – to mimic the concentrations of molecules in the cytosol
– and observe any differences between WT and R5L tau.
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6 Concluding Discussion
The domains of tau play vital roles in the function and dysfunction of tau
In these studies, we have added to the growing body of work highlighting the
importance of the proline rich region in tau’s conformation, function, and dysfunction.
Studies had previously shown how P2, the second half of the proline rich region, is
necessary for tubulin polymerization (50,51,66), and tau constructs used in aggregation
studies containing only the MTBR showed slower aggregation rates than constructs with
P2 and the MTBR (91,93).
We proposed three possible mechanisms for the initiation of tau aggregation in
the presence of polyphosphates (polyP) (Chapter 2): i) adopting an aggregation-prone
composition in which the PRR and MTBR compact and the N- and C-termini lose their
long-range contacts, ii) charge screening allowing for an increase of local concentration
of tau monomers, and iii) intermolecular cross-linking of multiple tau monomers. One
important observation was that the proline rich region appeared to have multiple possible
binding sites for polyP. There is an increase in diffusion time for the P1P2 construct (Fig.
2-3) and a change in conformation when probing the PRR using smFRET both in the fulllength construct (Fig. 2-1) and in the isolated fragment (Fig. 2-5). We also note that it’s
likely there are multiple binding sites as while the isolated P1P2 and P2-4R constructs
undergo a conformational change in the presence of polyP, the MTBR fragment by itself,
4R, does not. Additionally, the presence of P2 increases the rate of aggregation,
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particularly in the 3R isoform which would likely be missing additional potential binding
sites (Fig. 2-10).
The proline rich region also appears to play a role in the interaction between tau
and the plasma membrane. In our hands, the N-terminal domain didn’t appear to interact
with lipid membranes (Fig. 3-6). However, both the PRR and MTBR domains show
binding to neutral and charged lipid vesicles. When looking at uptake into SH-SY5Y
cells, constructs consisting of only the PRR domain behaved differently from the MTBRonly constructs. P1P2 also appeared to be present in the cytosol vs vacuoles, and
colocalized with a mitochondrial tracker instead of a lysosomal tracker like the other
constructs of tau tested (Fig. 3-1 and 3-2).
Additionally, interactions with both cell-derived vesicles model membranes
showed that PRR binds more consistently to the lipid vesicles, while in some cases also
able to passively diffuse across the membrane (Fig. 3-3, 3-4, 3-5). This was only
observed with P1P2 and not with the 4R constructs.
Interactions between the N-terminal domain and the PRR were further
demonstrated when comparing FRET efficiency values under different salt conditions: a
high molarity buffer that would screen some electrostatic charges and a low salt buffer
which is less likely to screen charge. When probing the combined N-terminal and proline
rich region, the ETeff was higher in the low salt buffer resulting in a more compacted
conformation of these two domains suggesting greater interactions (Fig. 4-3 and 4-4). As
P2 has been shown to be essential for tau’s function (50,51,65,66) and the N-terminal
role has a regulatory effect on microtubule polymerization by tau (65), the contacts made
with the proline rich region are likely vital for tau’s native function.
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The behavior of tau is highly dependent on the environment and its binding partners
A vital characteristic of IDPs is the change in conformation in different
environments and with binding to various binding partners. Here we show that tau does
indeed adopt different conformations under different buffer conditions and upon binding
to similar, yet structurally different, binding partners.
Comparing the FRET efficiency values between polyP and heparin tau undergoes
greater shifts in conformation in the presence of polyP (Fig. 2-12). Since this was
consistent when the heparin concentrations used were 1/4 and 4 times the equivalent
charge concentration of polyP300, it suggests that it isn’t a purely electrostatic interaction.
Additionally, since shorter chain lengths of polyP also showed decreased changes in
FRET efficiency (Fig. 2-7), it is likely that the possibility of forming intramolecular
interactions favors the conformational changes observed in tau.
When studying the interaction of tau to the lipid membranes, the presence of
charge appeared to have a secondary effect compared to the ordered or disordered phase
behavior of the membrane. When comparing binding to liquid ordered and disordered
vesicles, tau showed a higher binding affinity to liquid ordered vesicles. However, when
charge was added there was an overall decrease in binding affinity and there was no
major difference between the liquid disordered and liquid ordered vesicles (Fig. 3-6).
This suggests the possibility that tau preferentially binds to cholesterol rich lipid-rafts in
the plasma membrane, allowing for a high local concentration to aid in translocation
through the membrane.
This suggests, that while tau is a highly charged protein that can “stick” to
anything, its functional behavior is very specific to the molecules that it binds to.
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Events don’t happen in a vacuum
Tau function in cells is interconnected with various processes that are often
difficult to recapitulate in vitro in simple tertiary model systems. All the separate events
studied in this thesis, the initiation of aggregation, interaction with lipid membranes, cellto-cell propagation, and tubulin polymerization likely happen simultaneously in neuronal
cells and have interconnected effects on function and dysfunction.
However, understanding the mechanisms of individual events that tau is involved
in can help us target tau for diagnosis and treatment of neurodegenerative diseases that
are based on tau pathology. Understanding the roles each domain plays in both its native
function and the initiation of aggregation leading to disease, lays the groundwork for
targeting the individual domains for diagnosis and treatment of tauopathies.
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7

Materials and Methods

7.1 Protein purification and labeling
Tau constructs were purified based on previously published protocols (14,33).
Briefly, all variants were expressed with a cleavable N-terminal His-tag. After elution
from a nickel column with 400 mM imidazole, the imidazole concentration was reduced
through several buffer exchange cycles using Amicon concentrators (Millipore) and the
protein was incubated with tobacco etch virus (TEV) protease at 4 °C overnight. After a
second nickel column to remove the enzyme and the cleaved tag, the protein was further
purified by size-exclusion chromatography on a HiLoad 16/600 Superdex 200 Column
(GE Life Sciences).
For site-specific labeling with fluorophores, QuickChange mutagenesis was used
to change both native cysteines (C291 and C322) to serines and to introduce new
cysteines at desired locations. For single molecule FRET measurements, cysteines were
chosen to span domains of interest as described in the manuscript. For FCS
measurements, the protein was labeled with a single cysteine introduced near either the
N- or C-terminus. For labeling, freshly purified tau was first reduced with 1 mM DTT for
10 minutes and buffer exchanged into a labeling buffer (20 mM Tris pH 7.4, 50 mM
NaCl, and 6 M guanidine HCl) using Amicon concentrators (Millipore) (155). For
labeling with donor and acceptor fluorophores for single molecule FRET, protein was
incubated stirring at room temperature for an hour with donor fluorophore Alexa Fluor
488 maleimide (Invitrogen) at a 2:1 protein:dye ratio. The acceptor fluorophore, Alexa
Fluor 594 maleimide (Invitrogen) was then added in 5-fold molar excess and incubated
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stirring overnight at 4°C. For single labeling for FCS, Alexa Fluor 488 maleimide was
added in 5-fold molar excess to protein and incubated overnight stirring at 4 °C. Labeled
protein was buffer exchanged into 20 mM Tris (pH 7.4) and 50 mM NaCl and unreacted
dye was removed by passing the solution over a HiTrap Desalting Column (GE Life
Sciences).

7.2 Aggregation assays
Fibril formation of tau fragments was monitored using Thioflavin T fluorescence.
25 µM tau and 10 µM Thioflavin T were incubated in 40 mM potassium phosphate, 50
mM KCl pH 7.5 at 37 °C with 1 mM of different chain length of polyP (polyP kindly
provided by T. Shiba (Regenetiss, Japan)) or 18 µM heparin from porcine intestinal
mucosa (molecular weight 17–20 kDa; Sigma-Aldrich). The polyP concentration is in
monomer phosphate units and the heparin concentration was chosen to match the amount
of negative charge of the 1 mM polyP. Approximate equivalent charge concentrations of
heparin were calculated assuming 1.5 to 2 charges and an average molecular weight of
665 g/mol per disaccharide (156). The samples were agitated for 10 seconds before every
reading. The measurements were made in a black 96-well polystyrene microplate with
clear bottom (Greiners). Experiments were read in a Synergy HTX MultiMode
Microplate Reader (Biotec) with an excitation wavelength of 430 nm and emission
detected at 485 nm.
To ensure that the fluorophores did not interfere with the ability of tau to
aggregate, two P2-4R constructs (C244-C372 and C291-C322) were labeled on both
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cysteines with Alexa Fluor 594, to minimize interference with the Thioflavin T signal.
Ensemble aggregation kinetics were measured using 95% unlabeled tau and 5% labeled
tau; 100% unlabeled tau was used as a control (Fig. 5-1). After a plateau in the Thioflavin
T fluorescence was reached, the samples were centrifuged at 20,000g for 60 minutes to
pellet the aggregates. The incorporation of fluorescently labeled protein into aggregates
was calculated by quantifying the loss of fluorescence in the samples following
centrifugation to remove the aggregates, relative to an unaggregated sample (Fig. 6-1).
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Figure 6-1. Labeled tau is incorporated into aggregates. Representative kinetic traces
of ensemble aggregation measurements made using 100% unlabeled tau (black and gray)
and 95 % unlabeled ta/5% fluorescently labeled tau (dark and light orange) in the absence
or presence of 1 mM polyP14 are shown (a). The incorporation of fluorescent into the
aggregates is confirmed as described in the Materials and Methods. Kinetics were
quantified by T1/2 (b). These experiments were carried out twice to ensure reproducibility.
Representative kinetic traces of 4R aggregation as measured by an increase in Thioflavin
T fluorescence for 25 µM tau with 1 mM polyP or 18 µM heparin (c).
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7.3 Transmission electron microscopy (TEM) of tau-polyP fibers
Samples from the Thioflavin T aggregation assay were analyzed by TEM. Sample
(~5 µl) was applied onto a thin amorphous carbon layered 400-mesh copper grid (Pelco)
and incubated for 3 minutes before removing the liquid with Whatman paper. The grid
was washed twice with 5 µl ddH2O followed by two applications of 5 µl 0.75% uranyl
formate (pH 5.5 – 6.0). The liquid was aspirated, with care taken to not disturb the
sample. Grids were imaged at room temperature using a Morgagni microscope operating
at 100kV. Images were acquired on a CCD camera at 22,000x resulting in a sampling of
2.1 Å/pixel.

7.4 Single molecule FRET instrument and data analysis
Single molecule FRET measurements were performed on a lab-built instrument
based on an inverted Olympus IX-71 Microscope (Olympus) (14,33). The laser power
(488-nm diode-pumped solid-state laser, Spectra-Physics) was adjusted to 25-35 µW
before entering the microscope. Fluorescence emission was collected through the
objective, and photons were separated by an HQ585LP dichroic in combination with
ET525/50M and HQ600LP filters for the donor and acceptor photons, respectively (all
filters and dichroics from Chroma). Fluorescence signals were collected by 100 μm
diameter aperture fibers (OzOptics) coupled to avalanche photodiodes (Perkin-Elmer).
Photon traces were collected in 1 ms time bins for an hour.
All measurements were carried out at a protein concentration of ~30 pM at 20 °C
in 40 mM potassium phosphate, 50 mM KCl buffer pH 7.4 in 8-chambered Nunc
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coverslips (Thermo-Fisher) passivated with poly(ethylene glycol) poly(L-lysine) (PEGPLL) to reduce protein and polyP adsorption to the chamber.
To discriminate photon bursts of real events from background noise, a threshold
of 30 counts/ms for the sum of the donor and acceptor channels was applied (105).
Measurements were made of polyP samples in the absence of tau to determine the
background signal (see Eq. 2 below) as well as any spurious contribution to single
molecule FRET events. No photon bursts (as defined by the criteria above) were
observed for hour-long measurements of 20 µM polyP.
The photon traces were analyzed using MATLAB (Mathworks) based lab-written
software. For each event, the energy transfer efficiency (ETeff) value was calculated from:
ET!"" =

#! $%#"
(#! $%#" )()(#" (%#" )

(Eq. 1)

where I* and I+ are the fluorescence intensities collected in the acceptor and donor
channels, respectively. β accounts for fluorescence from the donor fluorophore on the
acceptor channel, and is measured each day varying between 0.7 and 0.85 for both the
home-built and commercial systems. γ accounts for differences in detection efficiency
and quantum yield for acceptor and donor fluorophores (26) and is measured every few
months; γ values used on the lab-built system were 1.36, 1.20 and 1.00 (changes in γ
occurred after major realignments or other adjustments to the instrument) and were 1.20
and 1.08 on the commercial Picoquant system (value changed after reinstalling the laser
and realigning the system). These individual ETeff values were compiled into histograms
and fit by multi-peak Gaussian functions to determine properties of the distributions. We
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compared ETeff histograms calculated with a correction for the background signal (Eq. 2)
(105) with those calculated without one (Eq. 1)
ET!"" =

(#! $,! )$%(#" $," )
((#! $,! )$%(#" $," ))()((#" $," )(%(#" $," ))

(Eq. 2)

Fitting of the histograms yielded equivalent mean ETeff values (Fig. 6-2).
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Figure 6-2. ETeff histograms without and with background subtraction. ETeff
histograms for three different tau constructs without (upper) and with (lower) subtracting
the average background signal from the individual events prior to calculating ETeff as
described in the Materials & Methods.
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Double-labeling of the proteins usually yields a mixture of labeled proteins with
donor-only, acceptor-only and donor-acceptor populations. The donor- and acceptor-only
labeled are easily separated in analysis. Donor-only labeled protein contributes to the
‘zero-peak’ (ETeff = 0) and acceptor-only labeled proteins does not give rise to a signal as
the acceptor is not directly excited (155).
For some constructs, the peak in the ETeff histograms arising from tau had low
values,

< 0.2, that overlapped significantly with the ETeff=0 peak, such that accurate

fitting of the tau peak position was not possible. For these constructs, direct excitation of
the acceptor fluorophore was used to discriminate between low ETeff events from tau and
those associated with the ETeff=0 peak (157). Measurements were made in pulsed
interleaved excitation FRET (PIE-FRET) mode on a MicroTime 200 inverse timeresolved confocal microscope (Picoquant). Laser power from 485 and 560 nm lasers
pulsed at 40 MHz, were adjusted to be ~30 µW before entering the microscope.
Fluorescence emission was collected through the objective and passed through a 100 µm
pinhole. Photons were separated by an HQ585LP dichroic in combination with
ET525/50M and HQ600LP filters and collected on photodiodes. ETeff and stoichiometry
factors were calculated using SymphoTime 64 software and the resultant histograms were
fit using Gaussian distributions as described above. Both the lab-built and Microtime 200
instruments were calibrated using 10 base pair, 14 base pair and 18 base pair dsDNA
standards.
Measurements were made using a ‘saturating’ concentration of polyP, defined as
a concentration where the addition of more polyP does not cause additional changes to
the ETeff histograms. This concentration was determined by a titration of polyP60 and
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polyP300 against a tau construct probing the PRR and MTBR (tauC149-C372) in the 4R
isoform (Fig. 2-9). The addition of polyP resulted the disappearance in the peak in the
ETeff histogram from unbound tau concomitant with the appearance of a peak
corresponding to polyP-bound tau (Figure 2-9). Binding curves were constructed by
calculating the areas of the histograms corresponding to unbound and bound tau, which
were fit to extract an approximate binding affinity using:
Y=

-#!$ [/]
1% ([/]

(Eq. 3)

where Y is the area of the fraction bound, Ymax is the maximum saturation (= 1.0), KD is
the apparent dissociation constant and X is the concentration of polyP by monomer Pi
unit (Fig. 2-9). A subset of polyP300 concentrations was also measured for 4R tau17-149 and
3R isoform of tau149-372. For some of the tau constructs and polyP chain lengths, the
polyP-bound peak was fully populated by 5 µM polyP (Fig. 2-9). However, for all of the
constructs measured, peak positions were stable after 20 µM polyP; this concentration
was chosen for ‘saturation’ measurements.

7.5 FCS instrument and data analysis
On the lab-built instrument, the laser power was adjusted to ~5 µW as measured
prior to entering the microscope. Fluorescence emission was collected through the
objective and separated from laser excitation using a Z488RDC long pass dichroic and an
HQ600/200M bandpass filter and focused onto a 50 µm diameter optical fiber directly
coupled to an avalanche photodiode. A digital correlator (FLEX03LQ-12,
Correlator.com) was used to generate the autocorrelation curves. All FCS measurements
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were carried out at ~20 nM protein at 20 °C in PEG-PLL coated Nunc coverslips. For
each measurement, 25 traces of 10 seconds were averaged to obtain statistical variations.
The autocorrelation function G(τ) is calculated as a function of the delay time τ and then
fit to a diffusion equation using a single-component fit using lab-written scripts in
MATLAB (The Mathworks)
2
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(Eq. 4)

Where N is the average number of molecules in the focal volume, s is the structure factor
(ratio of radial to axial dimensions) and τD is the translational diffusion time. Each
measurement was repeated a minimum of three times to calculate τD values and the error
is reported as s.e.m. The normalized change in diffusion time was calculated as (tau+polyPtau-polyP)/tau-polyP. Some FCS measurements were carried out on the MicroTime 200
instrument and analyzed using the SymphoTime 64 software.
Noncovalent cross-linking measurements were carried out using 25 µM unlabeled
4R, 20 nM single labeled 4R and 1 mM polyP or 18 µM heparin at 20 °C. Triplicate
measurements with 25 curves of 10 seconds were recorded immediately after mixing.
The cross-linking FCS measurements were carried out at a lower temperature (20 °C)
than the aggregation assays (37 °C). Aggregation occurs more slowly at lower
temperatures such that it is unlikely that large fibrillar aggregates are formed during the
duration of the FCS measurements.
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7.6 Tubulin-polyP competition assays
Tubulin was purified from bovine brain tissue using repeated cycles of
polymerization and depolymerization in the presence of a high-molarity PIPES buffer
(158). Before use, tubulin was clarified by centrifugation at 100,000g and bufferexchanged into phosphate buffer.
Competitive binding of tubulin and polyP to tau was measured by FCS. ~20 nM
P2-4R was incubated with 5 µM tubulin for 5 minutes at 20 °C. PolyP300 was added to
the tau-tubulin sample at concentrations ranging from 5 µM to 100 µM and incubated for
5 minutes before measurement. For each measurement, 25 curves of 10 seconds were
recorded and analyzed with a single-component fit (Eq. 4 above) using lab-written scripts
in MATLAB. Measurements were repeated in triplicate.

7.7 Statistical analysis
Data are presented as mean ± s.e.m. Statistical significance was calculated using
unpaired two-tailed tests with P<0.05 considered significant with a minimum of n=3 for
FRET, FCS and aggregation assays. The s.e.m. for the change in diffusion time was
calculated from repeats of the measurements (Fig 3). The s.e.m. for change in ETeff
(Table 5-2-1, 2-9, 2-3, 2-7) was calculated by propagation of error using (x12+x22)1/2
where x1 and x2 are the s.e.m of tau in the absence and presence of polyP, respectively.
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7.8 Phosphate assays to determine lipid concentrations
A colorometric phosphate is used to the determine the concentration of lipid
stocks and samples. A standard curve is built using a phosphate standard with 5 points
from 0 to 0.65mM phosphate. The volume of each standard sample is brough to 125 µl.
125 µl lipid samples are made in triplicate at an approximate concentration of 0.3 to 0.5
mM. 200 µl of 10% sulphuric was added to the samples and heated at 200 °C for one
hour. 25 µl of hydrogen peroxide was added to each sample and heated for another 45
minutes. Once all the solution evaporated, the samples were removed from heat and
allowed to cool to room temperature. 500 µl of water was added to the samples to
deactivate the hydrogen peroxide and vortexed. 500 µl of a solution of 9 parts 2.2% w/v
ascorbic acid and 1 part 5% w/v ammonium molybdate solution is added to the samples,
vortexed, and heated at 50 °C until color forms. UV spectra were read at 650 and 800 nM
and plotted on a standard curve to determine the concentration of the starting lipid
sample.

7.9 SH-SY5Y cell culture
SH-SY5Y cells (ATCC CRL-2266) were grown at 37 °C under 5% CO2 humidity
in Dulbecco’s Modified Eagle’s Medium (DMEM) with 10 % fetal bovine serum, 50
U/mL penicillin and 50 µg/mL streptomycin.
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7.10 Uptake Assays and Imaging Cells
Cells were plated on µ-slide 8 Well high Glass Bottom chambers (ibidi) 0.01%
poly-lysine solution (Sigma #25988-63-0, sterile filtered, MW 70,000-150,000) at a
concentration of 7x104 cells/ml/well. The cells were allowed to incubate for 24 – 48
hours before use in the assays.
For cell uptake assays, the media was removed and replaced with media
containing 200 nM of fluorescently labeled tau and allowed to incubate at 37 °C under
5% CO2 humidity until the desired time point. Media was then removed and replaced
before imagining the cells on either a Nikon eclipse Ti2 microscope illuminated with sola
light engine or on a MicroTime 200 inverse time-resolved confocal microscope
(Picoquant).
MitoTracker™ Red CMXRos (Thermo Fisher) and LysoTracker™ Deep Red
(Thermo Fisher) were stored at 4 °C and diluted in DMEM before adding to the plated
cells at a concentration of 10 nM per well.

7.11 Preparation and Imaging of GPMVs
T25 flasks (Sigma-Aldrich) were coated with a 0.01% poly-lysine solution
(Sigma #25988-63-0, sterile filtered, MW 70,000-150,000). Cells are plated and allowed
to reach ~75% confluency. Media was removed from the flasks and then washed three
times with GPMV buffer (10 mM HEPES, 150 mM NACl, 2 mM CaCl2 pH 7.4). Flasks
were then incubated, shaking at 37 °C in a solution of 25 mM paraformaldehyde and 2
mM DTT in GPMV buffer for 2-5 hours. Plates were monitored under the microscope for
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the formation of vesicles. GPMVs are harvested by decanting the solution into a Falcon
tube. The vesicles were allowed to settle for 15 minutes to an hour before use (159).
Vesicles were imaged 8-chambered Nunc coverslips (Thermo-Fisher) passivated
with poly(ethylene glycol) poly(L-lysine) (PEG-PLL). 5 µL of GPMVs were added to
250 µL in each well and incubated with 200 nM of fluorescently labeled tau before
imaging at the required time points on a Nikon eclipse Ti2 microscope illuminated with
sola light engine.

7.12 Preparation of GUVs
GUVs were prepared from lipid stocks, stored at 20 mg/mL solutions in chloroform
at -20°C for up to six months. To prepare the vesicles, appropriate volumes of each stock
solution were mixed, and 50 µl of a 5mM solution were spread on the conductive side of
Tin Indium Oxide coated slides (Delta Technologies, Stillwater, MN). The slides were
allowed to dehydrate to remove the chloroform in a vacuum for 4 hours or overnight.
Two slides with the same lipid mixture coating were sandwiched with 500 µl of the
desired aqueous buffer held in Silicon O-rings. A 2 V, 10 Hz alternating current was
applied to the slides for 1.5 hours in a heated block of 50 °C. The aqueous solution was
then harvested and either allowed to settle by itself or settled though a less dense solution
to allow the vesicles to settle to the bottom faster.
Vesicles were incubated with fluorescently labeled tau for 2 hours before imaging
in imaged 8-chambered Nunc coverslips (Thermo-Fisher) passivated with poly(ethylene

115

glycol) poly(L-lysine) (PEG-PLL) on a MicroTime 200 inverse time-resolved confocal
microscope (Picoquant)

7.13 Preparation of LUVs
LUVs were prepared from lipid stocks, stored at 20 mg/mL solutions in
chloroform at -20 °C for up to six months. To prepare the vesicles, appropriate volumes
of each stock solution were mixed, and the chloroform was evaporated under a gentle
stream of nitrogen. The samples were allowed to further dehydrate under vacuum for 4
hours or overnight. Lipids were rehydrated in the desired buffer and passed through 10
freeze-thaw cycles (30 seconds in liquid nitrogen, 2 minutes in water at 50 °C), and then
extruded 21 times through two 100 nm filters in an extruder (Avanti). The final lipid
concentration was determined using a phosphate assay.

7.14 Calculating fraction bound
The autocorrelation curves were analyzed using a two-component fit using labwritten scripts in MATLAB (The Mathworks).
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(Eq. 5)

where N is the average number of molecules in the focal volume, s is the structure factor
(ratio of radial to axial dimensions) and τD1 is the translational diffusion time of protein
alone, τD2 is the translational diffusion time of protein bound to vesicles and A is the
fraction of free protein. Fraction bound was calculated as (1 – A).
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7.15 Polymerization Assays
Polymerization assays were carried out in a The Infinite M1000 (Tecan). A 150 µL
solution of 10 µM tau and 20 µM tubulin were prepared on ice in BRB80 buffer. 1mM
GTP was added to the mixture immediately before adding the solution to a black 96-well
polystyrene microplate with clear bottom (Greiners) at 37 °C. The intensity was read for
45 minutes at 20 second intervals for each sample on the Tecan i-control software.
Formation of microtubules was confirmed by spinning down the samples and running the
supernatant and resuspended pellet on an SDS-page gel.

117

8 Appendix
8.1

This appendix chapter was adapted from Sanjula P. Wickramasinghe, Elizabeth Rhoades
(2020). Measuring interactions between tau and aggregation inducers with single
molecule Förster resonance energy transfer. Methods in Molecular Biology, 2141 755775.
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Abstract
Tau is an intrinsically disordered protein implicated in the pathogenesis of Alzheimer’s
disease and other neurodegenerative disorders. Here we describe the application of single
molecule Förster resonance energy transfer (smFRET) to characterization of the
interactions between tau and polyphosphate, an intracellular polymer which accelerates
tau aggregation. We describe the design of tau constructs, purification and fluorescent
labeling of tau and details of acquisition and analysis of smFRET data. The protocols
provided here outline an approach that may be applied to the study of other intrinsically
disordered proteins and their binding partners.
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Introduction
It is estimated that >40% of the mammalian proteome can be classified as being
entirely intrinsically disordered or containing disordered domains (1). Intrinsically
disordered proteins (IDPs) are generally enriched in charged and polar residues, with
relatively low fractions of hydrophobic residues, and do not form stable secondary or
tertiary structures in isolation (2). Despite their lack of stable structures, IDPs are
involved in a variety of cellular functions, including signaling pathways (3) and
membraneless organelles (4), as well as being implicated in a number of diseases (5).
Single molecule Förster resonance energy transfer (smFRET) is a powerful approach for
characterizing heterogenous conformational states of IDPs. FRET is the non-radiative
transfer of energy via a dipole-dipole mechanism from a donor fluorophore to an acceptor
fluorophore (6) The efficiency of transfer, ETeff, is strongly dependent on the distance
between the fluorophores (7). When both fluorophores are placed on the same protein, it
serves as a useful probe of conformational changes as a function of measurement
conditions. Intramolecular smFRET has been used to gain insight into unfolded states of
globular proteins (8), the role of disorder in allosteric regulation (9), conformational
states of disordered proteins involved in phase separation (10) and high affinity
interactions of disordered proteins in complexes (11).
Tau is an intrinsically disordered microtubule associated protein that is implicated
in a variety of neurodegenerative diseases collectively known as tauopathies (12). While
fibrillar aggregates of tau are the hallmark of these diseases, the molecular mechanisms
relevant to the initiation of tau aggregation are not well understood. Tau does not
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aggregate readily in vitro, and as such, aggregation is often studied in the presence of
anionic molecules such as heparin, arachidonic acid or polyphosphate (13-16). The low
protein concentrations (~pM) used in diffusion-based smFRET measurements (Figure 2)
disfavor aggregation, making intramolecular smFRET particularly useful for
characterizing domain-specific conformational changes relevant to tau aggregation in the
monomer protein.
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2. Materials
Prepare all solutions in ultrapure water unless otherwise stated.
2.1 Materials for Sample Preparation and Purification
2.1.1. Plasmids and Strains
1. Tau plasmid: We use the full-length human tau gene cloned into a pET-11 vector
with an N-terminal His-tag and a tobacco etch virus (TEV) cleavage site.
2. DH5α cells: DH5α cells are used for plasmid amplification.
3. BL21 cells: BL21 cells are used for protein expression.

2.1.2 Solutions, Media and Buffers
1. Ampicillin: 100 mg/ml stocks of ampicillin are made in water, filtered through a
0.22 µm filter and stored at -20 °C.
2. LB media: The lysogeny broth (LB) media is made at a concentration of 25 g/L
and autoclaved before use.
3. LB/agar/ampicillin plates: The LB/agar media is made with 25 g/L LB and 15 g/L
agar. Autoclave the solution and cool to ~60 °C before adding ampicillin to a final
concentration of 1 mg/mL. Pour the media into plates and allow to further cool
and solidify before storage at 4 °C.
4. Isopropyl β-D-1-thiogalactopyranoside (IPTG): IPTG is used to induce the
expression of protein. 1M IPTG stocks are made in water and passed through a
0.22 µm filter for storage at -20 °C.
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5. Phenylmethylsulfonyl fluoride (PMSF): PMSF is a protease inhibitor. 100 mM
PMSF stocks are made in 100% ethanol.
6. Lysis Buffer:
-

50 mM Tris HCl pH 8

-

500 mM NaCl

-

10 mM imidazole

-

1 mg/mL chicken egg white lysozyme

-

1 tablet of cOmplete EDTA-free protease inhibitor

-

1 mg/mL PMSF

7. Low Imidazole Buffer (Buffer A):
-

50 mM Tris HCl pH 8

-

500 mM NaCl

-

10 mM imidazole

8. High Imidazole Buffer (Buffer B):
-

50 mM Tris pH 8

-

500 mM NaCl

-

500 mM imidazole

9. Nickel Affinity Column: Nickel columns are packed with 5 mL Ni-NTA resin (we
use HisPurTM from Thermo Scientific) and equilibrated with Buffer A prior to use.
10. Dithiothreitol (DTT): DTT is a reducing agent. 1 M DTT stocks are made in water,
filtered through a 0.22 µm filter and stored at -20 °C.
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11. TEV protease: The protein is produced in house and activity verified with a TEV
Protease Activity Assay (Fluorometric) (Abcam, Biovision).
12. Tris(2-carboxyethyl)-phosphine (TCEP): TCEP is a reducing agent. 1M TCEP stocks
are made in water, passed through a 0.22 µM filter and stored at -20 °C.
13. Ethylenediaminetetraacetic acid (EDTA): EDTA is a chelating agent. EDTA can be
bought as a premade stock solution or made as a 1M stock solution in water.
14. Size Exclusion Buffer (Buffer C):
-

25 mM Tris pH 8

-

100 mM NaCl

-

1 mM EDTA

-

1 mM TCEP

15. FRET Buffer:
-

20 mM Tris HCl pH 7.4

-

50 mM NaCl

16. Labeling Buffer:
-

20 mM Tris HCl pH 7.4

-

50 mM NaCl

-

6 M Guanidinium chloride (GdnHCl)

17. Alexa Fluor Maleimide Dyes: AlexaFluor maleimide dyes are used to label the
proteins through reaction with reduced cysteine residues. Make 10 mg/mL
stocks by dissolving 1 mg of dye in 100 µL anhydrous dimethyl sulfoxide
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(DMSO). Aliquot the solution into smaller volumes (2 µl – 10 µl), flash freeze
and store at -80 °C.
18. PEG-PLL: Poly-L-Lysine (PLL) is chemically conjugated to polyethyleneglycol
(PEG) and used for passivation of sample chambers.
-

Dissolve PLL hydrobromide (PLL: Sigma) in a 50 mM borate buffer (pH 8.5) to
make 2.5 mL of a 40 mg/mL solution; vortex for 30 minutes.

-

Filter the PLL solution and add it to mPEG-SPA-2kDa (PEG: NANOCS) powder
to a final PEG concentration of 100 mg/mL.

-

Vortex the solution and incubate it in the dark for 6 hours at room
temperature.

-

Place the solution in 7kD MW dialysis tubing and dialyze overnight against 2 L
of water. The PEG-PLL solution will increase in volume 4-6x during dialysis.

-

Aliquot the PEG-PLL for storage at -20 °C.

19. eGFP: eGFP is produced in-house.
20. Polyphosphate (polyP):
-

We have used polyP provided by Prof. U. Jakob (University of Michigan)
through Dr. T Shiba (Regenetiss, Japan). Commercial sources are available
(Kerafast).

-

The average chain lengths are determined through polyP gel electrophoresis
based on the negative staining method of Smith and Morrissey (17).
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-

The polyP concentration can be determined by using a Toluidine blue assay
against a phosphorous standard curve.

-

PolyP is dissolved in HPLC-grade water and stored at -80 °C.

21. Fluorescence correlation spectroscopy (FCS) alignment solution: Alexa Fluor
Hydrazide 488 is dissolved in water to 20 nM.
22. smFRET standards: We use double stranded DNA with each strand labeled
with either the donor or acceptor fluorophore on the 5’ end (IDT). We use
three standards of different lengths: 10, 14 and 18 nucleotides. These give rise
to FRET efficiencies, ETeff (see below for details of measurements and
calculation of ETeff), of ~0.8, ~0.5 and ~0.3 respectively.
-

Dissolve the DNA to 2 µM in 100 µL of oligo hybridization buffer (10 mM Tris
HCl pH 8, 15 mM MgCl2, 100 mM NaCl) in a microcentrifuge tube.

-

Cover the tube in aluminum foil to prevent exposure to light.

-

Heat approximately 1 L of water until boiling, then remove from the heat.

-

Submerge the DNA reaction in the water and leave to cool overnight with
stirring.

-

Aliquot the reaction and store at 4 °C for regular use or -20 °C for long term
storage

2.2 SmFRET Instrument
While there are commercial options for smFRET instruments, a significant fraction of
smFRET measurements are carried out on lab-built instruments, such as ours (Figure 1).
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The description of the instrument below is specific to the use of AlexaFluor 488 as the
donor fluorophore and AlexaFluor 594 as the acceptor fluorophore.

Components:
- Inverted Olympus IX-71 Microscope
- 60x/1.2 NA water immersion objective (Olympus)
- 488 nm diode pumped solid-state laser (Spectra Physics)
- Z488rdc and HQ585LP dichroics (Chroma)
- 500LP, ET525/50M and HQ600LP filters (Chroma)
- Avalanche photodiodes (Perkin-Elmer)
- 50 and 100 µm diameter aperture optical fibers (OzOptics)
- Four channel USB correlator, Flex03LQ-12 (Correlator.com)
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3. Methods
3.1 Design of Tau Constructs for smFRET measurements
Tau has four main functional domains (Figure 2): the N-terminal domain (NTD: with
inserts N1 and N2), the proline rich region (PRR), the microtubule binding region
(MTBR: with three or four conserved repeat sequences, R1, R2, R3 and R4) and the Cterminal domain (CTD). Tau is found as six naturally occurring isoforms resulting from
alternative splicing of the two N-terminal inserts (0N, 1N and 2N) and the second repeat,
R2, of the MTBR (3R vs 4R).

Because IDPs like tau often exhibit domain-specific, non-cooperative behavior, a single
set of labeling sites may not be sufficient to capture all relevant conformational changes
(13, 18). To address this challenge, our strategy is to label the protein at multiple sets of
independent and overlapping sites. This allows us to probe tau domains within the
context of the full-length protein. To illustrate, in the full-length protein we place labels
at positions spanning the MTBR as well as spanning the PRR-MTBR (Figure 2) to
determine the relationship between the two domains. We may also probe the properties of
these domains in isolation in order to understand the impact of flanking regions on their
properties, e.g. a fragment consisting only of the MTBR or of the PRR-MTBR (Figure 2)
(19).
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3.1.1 Introduction of cysteines for labeling
1. Native cysteines at residues 291 and 322 in the tau isoforms containing all four
repeats are mutated to serines using site-directed mutagenesis (QuickChange).
2. Pairs of cysteines residues are introduced by site-directed mutagenesis to span
the different domains of interest. To illustrate, we mutated residues Q244 and
E372 (Figure 2) to cysteines to incorporate fluorophores which allow for probing
the MTBR.

3.1.2. Creation of tau isoforms and fragments
1. To investigate the behavior of the isolated domains, fragments are cloned from
the full-length tau plasmid.
2. For both isoforms and fragments, the construct plasmids are made by deleting
the necessary residues from the full-length plasmid.

3.2 Tau Expression and Purification
1. Transform tau into BL21 cells and plate on LB/agar/ampicillin plates. Select a
single colony for inoculation of a 5 mL starter culture (LB supplemented with 1
mg/mL ampicillin added just prior to growth). Incubate the starter culture
overnight and then add it to a larger volume of LB supplemented with 1 mg/mL
ampicillin. The size of the LB cultures for protein expression varies; typically, 1 L
is used for full-length constructs, while 0.5 L is used for fragments.
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2. Incubate the large volume LB culture for ~ 4 hours at 37 °C with shaking to reach
an OD at 600 nm between 0.4 and 0.6. Add IPTG to a final concentration of 1
mM to induce protein expression. Let the culture continue to grow either 4
hours at 37 °C or overnight at 16 °C. See Note 1.
3. Pellet the cells and resuspend the pellet in 30 mL Lysis Buffer per 1 L of LB. Lysed
cells can be stored at -80 °C until needed.
4. Thaw the sample and sonicate on ice for 100 seconds with a 1 second pulse
followed by 2 seconds of rest at a maximum power of ~ 35 W.
5. Centrifuge the cells at 20,000 xg for 30 min at 4 °C. Discard the pellet.
6. Filter the supernatant with a 0.22 µm filter to remove any residual cell debris.
For full-length tau, all of the following steps should be carried out at 4 °C unless
otherwise stated to minimize degradation of the protein. See Note 2.
7. Remove excess buffer from the Nickel Affinity column and mix with filtered
supernatant; incubate for 45 to 60 minutes with gentle shaking.
8. Allow the column material to settle and drain excess solution; wash the column
with additional Buffer A.
9. Step-elute the protein in ~15 mL Buffer B, collecting all 15 mL.
10. Concentrate and buffer exchange the sample into Buffer A using an Amicon
centrifugal filter unit with the appropriate cut off (10 kD for full-length and 3 kD
for fragments) to reduce the imidazole concentration. See Note 3.
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11. To cleave the His-tag, add DTT to a final concentration of 1 mM, followed by ~1
mg/mL TEV protease. Incubate overnight at 4 °C or for 3-4 hours at room
temperature with gentle shaking.
12. Remove DTT by buffer exchange into Buffer A using an Amicon filter unit.
13. As in step 7, incubate with the Nickel Affinity column for 45 to 60 minutes with
gentle shaking.
14. Collect the column flow-through, which will contain the cleaved tau; uncleaved
tau, cleaved His-tag and TEV protease will all be retained on the column bed.
15. Concentrate the protein sample and buffer exchange into Buffer C using an
Amicon filter unit.
16. Remove all remaining contaminants by passing the protein over a HiLoad 16/600
Superdex 200 size-exclusion column (GE Healthcare Life Sciences).
17. Detect and analyze the purity of the protein through SDS-PAGE of the fractions
collected from the size exclusion column. See Note 4.
18. Concentrate and buffer exchange the pure protein into FRET buffer. Either label
the protein immediately or aliquot it and flash-freeze in liquid nitrogen for
storage at -80 °C. See Note 5.
19. Determine the yield of the protein by absorbance at 280 nm. See Note 6.
20. Our yield at this stage is approximately 2 – 5 mg of tau per 0.5-1 L growth.

3.3 Labeling Tau for smFRET measurements
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1. Starting with an aliquot of tau from Step 18 of 3.2, add DTT to a final
concentration of 1 mM at room temperature and incubate for ~30 minutes.
2. Buffer exchange tau into Labeling Buffer using an Amicon filter unit.
3. Further concentrate the sample in the Amicon filter unit until to a final volume of
~500 µl. The tau concentration should be around 100 µM. See Note 7.
4. Remove protein to a small, clean glass vial (2 mL vial with a flat bottom) and add
the donor dye, Alexa Fluor 488 maleimide, at a 2:1 protein:dye ratio. Cover with
aluminum foil to protect the sample from light and incubate for 1 hour at room
temperature with stirring.
5. Add the acceptor dye, Alexa Fluor 594 maleimide, to 5x molar excess, cover with
foil and move to 4 °C. Continue incubation with stirring overnight. See Notes 8
and 9.
6. Remove the GdnHCl and some of the unreacted dye by buffer exchange into
FRET Buffer using an Amicon filter unit.
7. Remove any remaining unreacted dye by passing the solution over two coupled
HiTrap Desalting Columns (GE Life Sciences) equilibrated with FRET buffer.
Labeled tau elutes between 2.5 and 3 mL.
8. Flash freeze ~30 µL aliquots in liquid nitrogen and store at -80 °C. See Notes 10,
11 and 12.

3.4 Preparation of coverslips
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1. Measurements are made in Nunc Lab-Tek eight-well chambered borosilicate
coverslips.
2. Dilute the PEG-PLL in Millipore water. We generally use a 1:40 dilution.
3. Treat the coverslips for 1 minute in a plasma cleaner (Harrick Plasma) on high.
4. Immediately add 300 µL of the diluted PEG-PLL into each well and let incubate
overnight at room temperature.
5. The following morning, rinse the coverslips 8 – 10 times with Millipore water.
6. Fill the chambers with water and incubate for ~3 hours to overnight. Leave water
in the chambers until it they are needed for measurements. See Note 13.
7. Replace the water in one well with 200-250 µL of the appropriate sample for
measurements. See Note 14.

3.5. Checking alignment by measuring diffusion times of fluorescent standards.
Fluorescence correlation spectroscopy (FCS) can be used to measure the diffusion time
of fluorescently labeled molecules (20). The diffusion time is very sensitive to the
instrument settings, including alignment of the lasers, fibers/pinholes and filter. As such,
measuring the diffusion time of a well-characterized fluorescent sample on a daily basis
is a robust means of ensuring that the instrument is aligned and all components are
functioning. We use Alexa 488 hydrazide and eGFP at 20 nM as reference fluorophores
for this purpose. The 50 μm aperture optical fibers are to couple the fluorescence
emission to the avalanche photo diode detectors for FCS measurements (Figure 1).
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1. Adjust the laser power to 5 µW just prior to entering the microscope.
2. Collect 10 measurements of 10 seconds each of the reference fluorescence
standards. The autocorrelation curves are generated by the digital correlator.
3. Average the 10 autocorrelation curves and fit the average curve, G(τ), to
Equation 1 which describeds diffusion in three-dimensions of a single fluorescent
species:
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(Eq. 1)

where N is the average number of molecules in the focal volume, s is the ratio of
radial to axial dimensions of the focused laser and 𝜏5 is the translational diffusion
time of the fluorescent molecule.

3.6. Calibrate instrument with smFRET Standards
Following alignment, smFRET positive controls that span a range of ETeff values are
measured to ensure day-to-day reproducibility of smFRET measurements. We use
fluorescently labeled double-stranded DNA (Section 2.1.2). The 100 μm aperture optical
fibers are used to couple the fluorescence emission to the avalanche photo diode
detectors for all smFRET measurements.
1. Adjust the laser power to 30 µW prior to entering the microscope.
2. Dilute the smFRET standard to ~30 pM in 250 µL of FRET buffer (made with HPLC
grade water).
3. Collect a 10 minute (1 ms bin size) intensity trace.
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4. From this trace, calculate ETeff values, plot as a histogram and fit as described
below in Section 3.8. For any given day, the peak ETeff value from fitting the
histogram should fall within the standard deviation of the over-time peak ETeff
values.

3.7 SmFRET measurements of tau
1. Collect a 1 minute intensity trace (1 ms bin size) of the buffer. This serves as a
measure of the background intensity for the sample. Under ideal circumstances,
analysis of this trace as described below (Section 3.8) should show that no FRET
events were recorded.
2. Add ~25 - 50 pM labeled tau to the measurement well. This is on the order of
two 1000x dilutions of the thawed tau aliquots from Section 3.3.
3. Mix by pipetting 3-4 times.
4. Collect a 1 minute intensity trace (1 ms bins size). Analyze the trace as described
below in Section 3.8. We typically expect 200 – 400 FRET events per minute.
Even after only one minute, analysis should show two peaks in the ETeff
histogram: (1) one which has an average ETeff=0, corresponding to events from
protein with two donor fluorophores or a donor fluorophore and an inactive
acceptor fluorophore; and (2) a second peak which corresponds to tau with an
active donor and active acceptor.
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5. If the analyzed data looks as described in step 4, collect a time trace of 30-60
minutes. See Notes 14, 15 and 16.

3.8 Analysis of smFRET data
3.8.1. Calculating ETeff
1. As described in Section 3.7, intensity traces are collected in 1 ms time bins. Apply
a minimum photon-per-event threshold to discriminate between signal and
noise (21). This can be done empirically, by increasing the threshold value until
no events are detected in the background measurements (Section 3.7, step 1).
Alternatively, it can be done by comparing the number of events obtained from
photon traces of buffer in the absence and presence of tau over a range of
threshold values, selecting a threshold value which gives the highest ratio of
protein:buffer events (21). For our measurements, we sum the photons in the
donor and acceptor channels before applying a threshold. For the measurement
conditions described here, we typically use a threshold between 30 and 50
photons/bin; all bins with fewer than the threshold number of photons are
removed from the data set for further analysis.
2. Using the filtered data set, the ETeff for each time-bin is calculated as:
𝐸𝑇677 =

(8- $9- )$:(8. $9. )
((8- $9- )$:(8. $9. ))(;((8. $9. )(:(8. $9. ))

(Eq. 1)

where Ia and Id are the intensities in the acceptor and donor channels, respectively;
Ba and Bd are the average background intensities of the acceptor and donor
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channels, respectively, measured in Section 3.7, step 1; β is the bleed-through of
donor fluorescence into the acceptor channel and γ corrects for the difference in
quantum yields of the fluorophores and quantum efficiencies of the detectors. See
Notes 17 and 18.
3. Plot the resultant ETeff values as a histogram. As described in step 4 of Section
3.7, histograms will always consist of two peaks, one corresponding to the ETeff=
0 peak and the other corresponding to tau labeled with both a donor and an
acceptor. Fit the histograms with a sum of two Gaussian distributions to
determine the peak ETeff values and the widths.

3.9 SmFRET measurements with polyP or other aggregation inducers
1. Dilute polyP to 250 µM-1 mM in buffer and add the appropriate volume to a
measurement well. See Note 19.
2. Measure a 1 minute intensity trace of the polyP solution. Analyze this trace as
described above in 3.8, using a threshold determined for buffer in the absence of
polyP as a starting point. Ideally, this analysis should not yield any events that
exceed the threshold. See Note 20.
3. Add labeled tau, pipette 3-4 times to mix and repeat steps 4 – 5 from Section 3.7.
4. Depending on the goal of the experiments, it may be desirable to carry out
measurements over a range of polyP concentrations. Often, we make comparative
measurements between tau isoforms or for different labeling positions under
‘saturating’ conditions, meaning that adding more polyP does not cause additional
changes to the ETeff histograms. The concentration of polyP that results in
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‘saturation’ may differ for different chain lengths of polyP, for different tau
isoforms or fragments or even for labeling positions reporting on different tau
domains. These measurements may result in an additional peak in the histogram
plots. As described above, in addition to the ETeff=0 and tau in buffer peaks, there
will be a peak due to tau with polyP bound (Figure 3). If this is the case, then an
additional Gaussian distribution should be included in the fitting protocol. See
Note 21.
5. Similar measurements can be carried out with other aggregation inducers such as
heparin (13), RNA or lipid vesicles.

4. Notes
1. Tau fragments (i.e. the MTBR or PRR) are generally expressed at 37 °C for 4
hours, while the full-length protein is expressed overnight at 16 °C. Full-length
tau can be grown at 37 °C with a decrease in the final yield due to increased
protein degradation.
2. Tau fragments express at a higher yield and are less prone to degradation than
the full-length constructs. If desired, purification of the fragments may be carried
out at room temperature without a significant loss of yield or purity.
3. To maximize yield of the protein, rinse the membranes of the Amicon
concentrators, collecting the rinse buffer, following use. This removes some of
the protein that has adsorbed to the membranes.
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4. As is true for many IDPs, tau runs at a larger molecular weight band on SDS-PAGE
gels than its actual molecular weight. For example, the MTBR construct, which is
176 residues long and has a molecular weight=18.4 kDa runs at ~25 kDa on a 4 –
12 % acrylamide gel.
5. Repeatedly freeze-thawing tau may compromise its integrity and is therefore not
recommended. Aliquot protein in convenient volumes for a single set of planned
experiments.
6. The molar extinction coefficient for full-length tau is 7450 cm-1M-1. The MTBR
fragment has a molar extinction coefficient of 1490 cm-1M-1. The extinction
coefficients can be calculated using ProtParam or any similar protein sequence
tools.
7. While a higher concentration of tau (~100 µM as recommended above) generally
results in a higher labeling efficiency, concentrations as low as ~40 µM have
been used successfully.
8. Labeling as described here does not allow for site-specific conjugation of the
donor and acceptor fluorophores to the cysteines. More precisely, labeled
proteins will be a mix of donor at site A, acceptor at site B; donor at site B,
acceptor at site A; donor at sites A and B; acceptor at sites A and B. If sitespecific conjugation of the fluorophores is desired, then a combination of a
cysteine and an unnatural amino acid provide orthogonal chemical reactivities
that can achieve this (22).
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9. Pairs of donor-acceptor dye are chosen to best cover the expected distance
between the two probes or to match the requirements of the instrument, i.e.
available laser excitation wavelengths. Alexa 488 and Alexa 594 have a
theoretical Ro =60 Å, however the actual R0 is dependent upon the quantum
yield and emission of the donor fluorophore. Therefore, R0 may be sensitive to
the labeling positions, solution conditions, etc. and should be experimentally
determined for each labeled protein construct if accurate distance calculations
are desired (23).
10. Because tau adsorbs to the walls of the microcentrifuge tubes used for storage,
maintaining the protein at a high concentration during storage and until use
minimizes loss. We generally avoid diluting the protein below ~1-2 μM prior to
dilution into the measurement chambers.
11. The labeled protein should be subjected to a functional assay to ensure that the
labels do not significantly perturb its properties. For tau, aggregation of the
labeled protein measured by lighted scattering (24), Thioflavin T fluorescence
(25) or anisotropy of the acceptor fluorophore (26) and compared to unlabeled
protein under the same conditions is a reasonable proxy for a functional assay.
12. Mass spectrometry is a useful approach for ensuring that the majority of the
protein sample has two fluorophores conjugated.
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13. Coverslips may be stored filled with water for approximately one week. Some
tau variants are more likely to adsorb to the Nunc chamber surfaces than other;
longer incubations of the wells in water may help alleviate this issue.
14. Inhomogeneities in the PEG-PLL coating of the coverslips can result in
inconsistent measurements or ETeff histograms that do not show evidence of
distinct populations or loss of signal due to protein adsorption or precipitation.
There may be well-to-well variability of the PEG-PLL coating and in some cases
simply moving to a new well will resolve issues. Alternatively, the use of
unlabeled tau to passivate the sample chambers before the addition of labeled
tau and/or polyP may also be helpful but may complicate measurements were
precise protein concentrations are required.
15. The number of events of the measurement should be monitored as a function of
time. If there is significant loss of events, this usually reflects precipitation of the
protein or adsorption to the sample chamber. Some attrition in the number of
events over time may be expected, especially for samples containing polyP. A
loss of ~20% is not problematic, if analysis of events collected early in the run
and those collected later in the run yield comparable results. A measurement
should be aborted if peaks are not distinguishable and the histogrammed data
appears relatively featureless from ETeff= 0 to 1.
16. In assessing our data, we often compare peak ETeff values obtained by fitting the
histograms as described here. However, if one wishes to calculate distances
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based on the peak ETeff values, there are a number of polymer models
appropriate for IDPs that may be solved numerically for this purpose (27).
17. b corrects for fluorescence from the donor fluorophore that is detected by the
acceptor photodiode. We typically determine this on a daily basis. Use a 20 nM
solution of Alexa Fluor 488 hydrazide, collect a 60 second intensity trace in both
the donor and acceptor detectors. Calculate β as
𝛽=8

8-

(Eq. 2)

- (8.

where Ia=intensity of acceptor channel and Id=intensity of donor channel.
18. g accounts for differences in the quantum yields of the donor and the acceptor
fluorophores, the use of bandpass filters which select only a portion of emitted
photons and differences in the quantum efficiencies of the detectors:
< =

𝛾 = < - =-

. .

(Eq. 3)

Where na and nd are the detection efficiency of the acceptor and donor
detectors respectively and øa and ød are the quantum yield of acceptor and
donor fluorophores respectively (28). We typically determine g every 3-4
months. To do so, make stock concentrations of Alexa Fluor 488 hydrazide and
Alexa Fluor 594 hydrazide with equal absorbances at the wavelength of donor
excitation (488 nm for our example). Make serial dilutions of each dye solution.
Dilute the initial solutions equally – the acceptor sample will be much more
concentrated than the donor sample, as its fluorescence when excited at the
donor wavelength is much less. Measure fluorescence intensities of the dyes on
142

the smFRET instrument using low laser power, as these solutions are much
higher concentration (μM) that those used for smFRET. Plot of the intensities of
the Alexa 594 fluorescence on the y-axis versus the Alexa 488 fluorescence on
the x axis. The slope of a straight line fit to this data is g.
19. PolyP samples should only be subjected to a few freeze-thaw cycles. Therefore it
is useful to have many aliquots of polyP at concentrations convenient for only
one or two sets of measurements.
20. Some binding partners increase the background signal over buffer and a higher
threshold may be required.
21. For labeling positions which give rise to low peak ETeff values (<0.2), it may not
be possible to distinguish events arising from donor-acceptor labeled protein
from the ETeff=0 peak using an instrument as described here (Figure 3).
Alternating laser excitation (ALEX) (29, 30) or pulsed interleaving excitation (PIE)
(31) uses a second laser to directly excite the acceptor fluorophore.
Measurements are made with switching between the donor and acceptor
excitation lasers and correlating the detected photons with the appropriate
excitation pulse. This allows for discrimination of true low ETeff events from
donor-acceptor labeled protein (which will have a signal when directly excited by
the acceptor laser) and ETeff =0 events from donor-only labeled protein (which
will not have a signal when excited by the acceptor laser).
5. Figures
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Figure 1. Schematic of components of smFRET instrument. The cartoon of the focused
laser shows a donor-acceptor labeled molecule diffusing through it, giving rise to a
‘burst’ of photons in both the donor and acceptor channels as shown in the time-trace
below it.
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Figure 2. SmFRET of 2N4R tau. Schematic of tau with functional domains noted (a).
SmFRET histograms of tau constructs in the absence (dark gray, dashed lines) and
presence (light grey, solid lines) of saturating concentrations of polyP of chainlength 300.
The left-hand column shows probes of different domains in the same construct: NTD (b),
PRR and MTBR (c) and CTD (d). The right hand column shows probes of the same
domain – the MTBR–in different constructs: full-length tau (e), a fragment with part of
the PRR and the MTBR (f) and the isolated MTBR (g). Figure adapted from (32).
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Figure 3. Titration of polyP of length 300 into tau. With increasing polyP
(concentration is indicated), the low ETeff peak corresponding to tau in buffer shrinks,
concurrent with the appearance of a higher ETeff peak from tau with polyP bound. These
plots illustrate the challenges of accurately measuring low ETeff events arising from
donor-acceptor labeled protein from the artifactual ETeff=0 peak. The data for the
histograms marked with an * were acquired in PIE-FRET as described in Note 18 to
eliminate the ETeff=0 peak. Figure adapted from (32).
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8.2

This appendix chapter contains sections adapted from Chih Hung Lo, Colin KinWye Lim, Zhipeng Ding, Sanjula P. Wickramasinghe, Anthony R. Braun,
Elizabeth Rhoades, David D. Thomas, Jonathan N. Sachs (2019). Targeting the
ensemble of heterogeneous tau oligomers: A novel small molecule screening
platform for disrupting toxic tau oligomers in cells. Alzheimer’s and Dementia
Journal. 15(11) 1489 – 1502.

* I collected the single molecule FRET data shown in Fig. 5a-c (Fig. 1a-c below).
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Summary
The Sachs lab reports on a technology platform developed to directly monitor
spontaneous tau oligomerization in cells based on fluorescence lifetime detection (1).
This technology employs distinct FRET biosensors that express full-length tau and
fluorescent protein fusion constructs in live cells to monitor inter- and intra- molecular
tau interactions within live cells. The use of full-length tau allowed to monitor only the
formation of oligomer ensembles, instead of fibril of tau, as 2N4R-WT does not form
fibrils without seeding.
Using this technology, the small molecule MK-866, was identified as a compound
that directly binds tau and attenuates the FRET within live cells, showing a decrease in
tau-tau interactions and thus, less oligomer formation. The mechanism of action of MK866 was elucidated using smFRET to show that molecule binds to the proline rich region
and microtubule binding region of tau and results in an unfolding of the two termini. This
effect recapitulated using intra-molecular FRET biosensors.
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Results
MK-886 specifically perturbs the PRR/MTBR of tau monomer and induces
conformational changes of the cellular tau intra-molecular biosensor
To further investigate the mechanism of action of MK-886, we used singlemolecule FRET (smFRET) to examine the effect of MK-886 on monomeric tau. Using
two different doubly fluorescent-labeled tau constructs (labeled at the proline rich
region/microtubule binding region (PRR/MTBR) or at the N-terminal domain) (2), we
monitored the conformation of two distinct regions of tau (Fig. 1A). The smFRET shows
that MK-886 causes a substantial increase in FRET for the PRR/MTBR targeted
construct (Fig. 1B) but only a minor decrease in FRET for the N-terminal domain
construct (Fig. 1C). This suggests that MK-886 specifically binds and induces a
conformational change in tau monomer at the PRR/MTBR region, resulting in a
subsequent loss of interactions between the N-terminal domain and the PRR/MTBR. To
determine whether MK-886 also perturbs the monomer conformation of tau in cells, we
tested the compound with a cellular tau intra-molecular FRET biosensor (GFP-tau-RFP).
The intra-molecular FRET biosensor has a basal 6% FRET signal, illustrating the intramolecular interactions arising from the paper-clip monomeric structure in which the Nand C-terminus of tau are folded to close proximity (3). Treatment with MK-886 reduced
intra-molecular FRET with an EC50 of 2.12 μM, similar to that of oligomer modulation,
suggesting that the change in conformational states of oligomers is due in part to
perturbation of the tau monomer (Fig. 1D).
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It has been suggested that the folding over of tau’s two termini to form the classic
“paper-clip” structure is due to electrostatic interactions that arise from the opposite net
charges of the N-terminal and MTBR domains (3). While this global folding is specific, it
has been shown to be a rather weak interaction (3). We speculate that the binding of MK886 to the PRR/MTBR of tau may shield these interactions and lead to an opening of the
two termini, resulting in the observed decrease in FRET of the intra-molecular FRET
biosensor. From our previous observations with smFRET on tau constructs, this type of
conformational change is often accompanied by the PRR/MTBR becoming substantially
more compact (increase in FRET) in recombinant protein systems (2).
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Figure 1. MK-886 binds and perturbs tau monomer conformation. (A) Singlemolecule FRET (smFRET) measurements in the absence and presence of MK-886 with
WT 2N4R tau double labeled at the proline-rich region/microtubule binding region
(PRR/MTBR, left) or at the N-terminal domain (right). Tau schematic represents the
labelling position for each construct. The black line is drawn from the peak of the
histogram in buffer for comparison with DMSO and MK-886 samples. Representative
histograms are shown. (B) Quantification of the smFRET measurements indicates that the
PRR/MTBR becomes substantially more compact (increase in FRET) upon binding MK886 (5 μM) (A, bottom left) when compared to tau in buffer (A, top left) or DMSO (A,
middle left) while the N-terminal domain (C) shows only minor differences in the
presence of MK-886 (5 μM) (A, right). (D) FRET analysis of the dose response of MK886 in the cellular tau intra-molecular biosensor indicates an EC50 value of 2.12 μM,
similar to that of oligomer modulation, suggesting that the change in conformational
states of oligomers is due in part to conformational changes of tau monomer. Data are
means ± SD of three independent experiments. *P < 0.05, ***P < 0.001 and n.s. indicates
not significant by two-tailed unpaired t test.
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